Harvard Medical School/Harvard School of Dental Medicine
Curriculum Vitae

Date Prepared: March 24, 2016

Name: Paola Silvia Dal Cin

Office Address: Department of Pathology
Brigham and Women's Hospital
75 Francis Street
Shapiro 5-058
Boston, MA 02115

Home Address: 43 Prince St #2
Brookline, MA 02446

Work Phone: 857-307-5124

Work E-Mail: pdalcin@partners.org

Work FAX: 857-307-1522

Place of Birth: Godega di S. Urbano, Treviso, Italy

Education

1967-1972	B.S.	Scientific School	Vittorio Veneto, Treviso, Italy
1972-1977	M.S.	Biology Dr. Romano Tenconi	University of Padua, Italy
1982-1986	Ph.D.	Genetics Dr. Marco Fraccaro	University of Pavia, Italy

Postdoctoral Training

1986-1987 Cancer Research Scientist
Dr. AA Sandberg
Department of Genetics and Endocrinology, Roswell Park Memorial Institute, Buffalo, NY

1987-1988 Research Associate
Dr. AA Sandberg
The Cancer Center of the Southwest Biomedical Research Institute, Scottsdale, AZ

Faculty Academic Appointments

1984-1986	Visiting Scientist	Department of Genetics and Endocrinology, Roswell Park Memorial Institute, Buffalo, NY

1988-1994	Research Associate	Center for Human Genetics, University of Leuven, Belgium
1993 (March)	Visiting Scientist	Department of Genetics, University of Pretoria, South Africa
1994-1996	Lector	Center for Human Genetics, University of Leuven, Belgium
1997-1999	Docent	Center for Human Genetics, University of Leuven, Belgium
1999-2012	Associate Professor	Department of Pathology, Harvard Medical School, Boston, MA
2013-	Professor	Department of Pathology, Harvard Medical School, Boston, MA

Appointments at Hospitals/Affiliated Institutions

1975-1977	Assistant Cytogeneticist	Unit of the Pediatric Clinic, University of Padua, Italy
1977-1978	Cytogeneticist	● Instituto Medicina Experimental, Universidad Central de Venezuela ● Unidad de Genetica, Instituto de Anatomia, Caracas, Venezuela
1978-1984	Cytogeneticist	Clinical and Research Laboratories, Centro Medico Docente La Trinidad, Caracas, Venezuela
1988-1999	Cytogeneticist	Center for Human Genetics, University of Leuven, Belgium
1999-	Associate Cytogeneticist	Cytogenetics Laboratory, Department of Pathology, Brigham and Women's Hospital, Boston, MA
2000-	Affiliate Faculty	Dana-Farber/Harvard Cancer Center, Leukemia/Lymphoma Myeloma and Sarcoma programs, Boston, MA
2002-	Affiliate Faculty	Molecular Genetic Pathology Training Program, Harvard Medical School, Boston, MA
2002-	Affiliate Faculty	American Board of Medical Genetics Training Program, Harvard Medical School, Boston, MA
2002-	Affiliate Faculty	Hematopathology Fellowship, Massachusetts General Hospital Boston MA

Other Professional Position

2007-	Consultant	MEDACorp

Committee Service

Local

1999- Cancer and Leukemia Group B (CALGB), Cytogeneticist, Brigham and Women's Hospital

2005- Chronic Lymphocytic Leukemia (CLL) Research Consortium, Cytogeneticist, Brigham and Women's Hospital and Dana Farber Cancer Institute.

2006- Children's Oncology Group (COG), Cytogeneticist, Brigham and Women's Hospital.

National

2010 The Cancer and Leukemia Group B (CALGB), Member, Spring Karyotype Review Committee. The Ohio State University, Columbus, OH

2010 American Society of Hematology (ASH) 52nd Annual Meeting, Abstract review committee member for Category 611A - *Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis*

2011- Cancer and Leukemia Group B (CALGB): Permanent Member, Karyotype Review Committee. The Ohio State University, Columbus, OH

International

1989-1995 Project Management Group of the European Community Concerted Action
Member, Program on Molecular Cytogenetics of Solid Tumors, Brusselles, Belgium

1994-2001 Chromosome And MorPhology (CHAMP)
Founding Member, Study Group on Mesenchymal Tumors, Leuven, Belgium

1999-2000 World Health Organization (WHO) Collaborative Consensus Conference on Public Health and Clinical Significance of Premalignant Alterations in the Genito-Urinary Tract. Stockholm, Sweden.

2002 Working Group Meeting on the WHO Classification of Tumors of Soft Tissue and Bone, Lyon, France

2004- Atlas of Genetics and Cytogenetics in Oncology and Haematology. Poitiers, France
Member, Board of Directors
URL: http://www.infobiogen.fr/services/chromcancer

Professional Societies

1984 - The Association of Cytogenetic Technologists, Member
1988 - American Association for Cancer Research, Member
1990 - 1999 Benelux Association for Pediatric Oncology, Member

1990 -1999	European Society of Human Genetics, Member
1991 -1999	European Association for Cancer Research, Member
1995-	Connective Tissue Oncology Society (CTOS), Member
1999 -	American Society of Human Genetics, Member
2000-2005	American College of Medical Genetics, Member
2001 -	International Society of Bone and Soft Tissue Pathology, Member
2003-2006	CTOS, Board of Directors
2009 -	United States and Canadian Academy of Pathology, Member

Editorial Activities

- *Ad hoc* Reviewer

American Journal of Pathology
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer
Cancer Genetics and Cytogenetics
Cancer Genetics
Cancer Research
Clinical Cancer Research
Genes Chromosomes and Cancer
Histopathology
International Journal of Cancer
Journal of Molecular Diagnostics
Modern Pathology
PLoS ONE
Virchows Archiv

- Other Editorial Roles

1988-2008	Assistant Editor	Cancer Genetics and Cytogenetics
2009-2010	Associate Editor	Cancer Genetics and Cytogenetics
2011 -	Board Member	Cancer Genetics
2011 -	Board Member	Molecular Cytogenetics
2016 -	Board Member	American Journal of Hematology

Report of Scholarship

Publications

Research investigations

1. Limon J, Rao U, **Dal Cin P**, Gibas Z, Sandberg AA. Translocation 13; 22 in a hemangiopericytoma. Cancer Genet Cytogenet 1986; 21:309-318.

2. Limon J, **Dal Cin P**, Sandberg AA. Application of long term collagenase disaggregation for the cytogenetic analysis of human solid tumors. Cancer Genet Cytogenet 1986; 23: 305-313.

3. Limon J, **Dal Cin P**, Sandberg AA. Cytogenetic findings in a primary leiomyosarcoma of the prostate. Cancer Genet Cytogenet 1986; 22:159-167.

4. Limon J, **Dal Cin P**, Sandberg AA. Translocations involving the X chromosome in solid tumor. Presentation of two sarcomas with t(X;18)(q13;p11). Cancer Genet Cytogenet 1986; 23:87-91.

5. Limon J, Turc-Carel C, **Dal Cin P**, Rao U, Sandberg AA. Recurrent chromosome translocations in liposarcoma. Cancer Genet Cytogenet 1986; 22: 93-94.

6. Sait S, **Dal Cin P**, Sandberg AA. t(Y;18) in AML (FAB M4). Cancer Genet Cytogenet 1986; 22: 367-368.

7. Turc-Carel C, **Dal Cin P**, Rao U, Karakousis C, Sandberg AA. Cytogenetic studies of adipose tissue tumors. I. A benign lipoma with t(3;12)(q28;q14). Cancer Genet Cytogenet 1986; 23:283-299.

8. Turc-Carel C, Limon J, **Dal Cin P**, Rao U, Karakousis C, Sandberg AA. Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet 1986; 23:291-298.

9. Sait S, **Dal Cin P**, Sandberg AA. Recurrent involvement of 11q13 in ANLL. Cancer Genet Cytogenet 1986; 26:351-354.

10. Turc-Carel C, **Dal Cin P**, Limon J, Li F, Sandberg AA. Translocation X;18 in synovial sarcoma. Cancer Genet Cytogenet 1986; 23:93.

11. Limon J, **Dal Cin P**, Kakati S, Huben R, Sandberg AA. Cytogenetic findings in primary adrenocortical carcinoma. Cancer Genet Cytogenet 1986; 26: 271-277.

12. Turc-Carel C, **Dal Cin P**, Limon J, Rao U, Li FP, Corson JM, Zimmerman R, Parry DM, Cowan

JM, Sandberg AA. Involvement of X chromosome in primary cytogenetic change in human neoplasia. Non-random translocation in synovial sarcoma. Proc Natl Acad Sci USA 1987; 84:1981-1985.

13. Turc-Carel C, **Dal Cin P**, Sandberg AA. Non-random translocation in extraskeletal myxoid chondrosarcoma. Cancer Genet Cytogenet 1987; 26:337.

14. Limon J, **Dal Cin P**, Gaeta J, Sandberg AA. Translocation t(4;11)(q35;p13) in an adrenocortical carcinoma. Cancer Genet Cytogenet 1987; 28:343-348.

15. Karakousis C, **Dal Cin P**, Turc-Carel C, Limon J, Sandberg AA. Chromosome changes in sarcomas. A new diagnostic parameter. Arch Surg 1987; 122:1257-1260.

16. Limon J, **Dal Cin P**, Sait S, Karakousis C, Sandberg AA. Chromosome change in metastatic human melanoma. Cancer Genet Cytogenet 1988; 30:201-211.

17. **Dal Cin P**, Rao U, Turc-Carel C, Sandberg AA. Translocation (7;21) in a lipoma. Cancer Genet Cytogenet 1988; 30:17-22.

18. **Dal Cin P**, Boghosian L, Sandberg AA. Chromosome changes in a prostatic leiomyosarcoma. Cancer Genet Cytogenet 1988; 30:339-340.

19. Turc-Carel C, **Dal Cin P**, Rao U, Karakousis C, Sandberg AA. Recurrent breakpoints at 9q31 and 22q12.2 in extraskeletal myxoid chondrosarcoma. Cancer Genet Cytogenet 1988; 30:145-150.

20. **Dal Cin P**, Boghosian L, Sandberg AA. Cytogenetic findings in leiomyosarcoma of the small bowel. Cancer Genet Cytogenet 1988; 30:285-288.

21. Fan YS, Baer MR, Sait S, **Dal Cin P**, Prentice TC, Preisler HD, Sandberg AA. An acquired robertsonian translocation dic(14;14)(p11;p11) in a patient with a myelodysplastic syndrome following treatment of multiple myeloma. Cancer Genet Cytogenet 1988; 30: 133-137.

22. **Dal Cin P**, Sandberg AA. Cytogenetic findings in a supratentorial ependymoma. Cancer Genet Cytogenet 1988; 30: 289-293.

23. Turc-Carel C, **Dal Cin P**, Carr K, Sandberg AA. Normal blood cells from patients with adipose tissue tumors with rearrangements at 12q13-14 do not express fra(12)(q13.1). Cancer Genet Cytogenet 1988; 31: 35-39.

24. Fan YS, Rowe JM, **Dal Cin P**, Sandberg AA. A Translocation t(9;11)(p11;q23) in T-cell acute lymphoblastic leukemia (FAB-L2). Cancer Genet Cytogenet 1988; 31: 263-269.

25. **Dal Cin P**, Turc-Carel C, Sandberg AA. Consistent involvement of band 12q14 in two different translocations in three lipomas from the same patient. Cancer Genet Cytogenet 1988; 31: 237-240.

26. Turc-Carel C, **Dal Cin P**, Boghosian L, Terkzakarian J, Sandberg AA. Consistent breakpoints in

region 14q22-q24 in uterine leiomyoma. Cancer Genet Cytogenet 1988; 32:25-31.

27. Psihramis KE, **Dal Cin P**, Dretler SP, Prout GR Jr, Sandberg AA. Further evidence that renal oncocytoma may have malignant potential. J Urol 1988; 139:585-587.

28. **Dal Cin P**, Boghosian L, Crickard K, Sandberg AA. t(10;17) as the sole chromosome change in a uterine leiomyosarcoma. Cancer Genet Cytogenet 1988; 32:263-266.

29. **Dal Cin P**, Huben R, Li FP, Prout GR, Sandberg AA. New cytogenetic subtype of renal tumors. Cancer Genet Cytogenet 1988; 32: 313.

30. Boghosian L, **Dal Cin P**, Sandberg AA. A deletion of chromosome 7 may characterize a subgroup of uterine leiomyoma. Cancer Genet Cytogenet 1988; 34:207-209.

31. Kakati S, Limon J, **Dal Cin P**, Pietrzak E, Kinniburgh AJ, Li FP, Sandberg AA. Abnormally banded region in a poorly differentiated sarcoma is not correlated with amplification of c-myc or c-mos proto-oncogenes. Cancer Genet Cytogenet 1988; 34:111-115.

32. **Dal Cin P**, Li FP, Prout GR, Huben RP, Limon J, Ferti-Passantonopoulou A, Richie JP, Sandberg AA. Involvement of chromosomes 3 and 5 in renal cell carcinoma. Cancer Genet Cytogenet 1988; 35: 41-46.

33. Sait S, **Dal Cin P**, Sandberg AA. Consistent chromosome changes in leiomyosarcoma. Cancer Genet Cytogenet 1988; 35: 47-50.

34. **Dal Cin P**, Talcott J, Abrams J, Li FP, Sandberg AA. ins(10;19) in an endometrial stromal sarcoma. Cancer Genet Cytogenet 1988; 36:1-5.

35. Turc-Carel C, **Dal Cin P**, Boghosian L, Leong SPL, Sandberg AA. Breakpoints in benign lipoma may be either at 12q13 or 12q14. Cancer Genet Cytogenet 1988; 36:131-135.

36. Sait S, **Dal Cin P**, Ovanessoff S, Sandberg AA. A uterine leiomyoma showing both t(12;14) and del(7) abnormalities. Cancer Genet Cytogenet 1989; 37:157-161.

37. Sait S, **Dal Cin P**, Leong S, Karakousis C, Harris K, Rao U, Sandberg AA. Involvement of 6p in benign lipomas. A new cytogenetic entity? Cancer Genet Cytogenet 1989; 37: 281-283.

38. Speleman F, **Dal Cin P**, De Potter K, Laureys G, Roels HJ, Leroy J, Van Den Berghe H. Cytogenetic investigation on a case of congenital fibrosarcoma. Cancer Genet Cytogenet 1989; 39:21-24.

39. Boghosian L, **Dal Cin P**, Turc-Carel C, Karakousis C, Rao U, Sait S, Sandberg AA. Three possible cytogenetic subgroups of leiomyosarcomas. Cancer Genet Cytogenet 1989; 43: 39-49.

40. **Dal Cin P**, Gaeta J, Huben R, Li FP, Prout GR, Sandberg AA. Renal cortical tumors. Cytogenetic characterization. Am J Clin Pathol 1989; 92: 408-414.

41. Speleman F, De Telder V, De Potter K, **Dal Cin P**, Van Daele S, Benoit Y, Leroy J, Van Den Berghe H. Cytogenetic analysis of a mesenchymal hamartoma of the liver. Cancer Genet Cytogenet 1989; 40: 29-32.

42. **Dal Cin P**, Drochmans A, Moerman Ph, Van Den Berghe H. Isochromosome 12p in mediastinal germ cell tumor. Cancer Genet Cytogenet 1989; 42: 243-251.

43. Cuneo A, Kerim S, Van Den Berghe E, Van Orshoven A, Rodhain J, Bosly A, Zachee P, Louwagie A, Michaux JL, **Dal Cin P**, Van Den Berghe H. Translocation (6;9) occurring in acute myelofibrosis, myelodysplastic syndrome and acute non-lymphocytic leukemia suggests multipotent stem cell involvement. Cancer Genet Cytogenet 1989; 42: 209-219.

44. Cuneo A, Mecucci C, Kerim S, Vandenberghe E, **Dal Cin P**, Van Orshoven A, Rodhain J, Bosly A, Michaux JL, Boogaerts M, Carli MG, Castoldi G, Van Den Berghe H. Multipotent stem cell involvement in megakaryoblastic leukemia. Cytological and cytogenetic evidence in 15 patients. Blood 1989; 74: 1781-1790.

45. Hashimura T, Tubbs R, Connelly R, Caulfield MJ, Trindade CS, Mcmahon JT, Galetti TP, Edinger M, Sandberg AA, **Dal Cin P**, Sait S, Pontes JE. Characterization of two cell lines with distinct phenotypes and genotypes established from a patient with renal cell carcinoma. Cancer Res 1989; 49: 7064-7081.

46. Speleman F, De Potter C, **Dal Cin P**, Mangelschots K, Ingelaere H, Laureys G, Benoit Y, Leroy J, Van Den Berghe H. i(12p) in a malignant ovarian tumor. Cancer Genet Cytogenet 1990; 45:49-53.

47. Kerim S, Stul M, Mecucci C, Vandenberghe E, Cuneo A, **Dal Cin P**, Michaux, JL, Louwagie A, Cassiman JJ, Van Den Berghe H. Rearrangements of immunoglobulin and TCR genes in lymphoid blast crisis of Ph+ chronic myeloid leukaemia. Brit J Haematol 1990; 74: 414-419.

48. Cuneo A, Van Orshoven A, Michaux JL, Boogaerts M, Louwagie A, Doyenne Ch, **Dal Cin P**, Fagioli F, Castoldi G, Van Den Berghe H. Morphologic, immunologic and cytogenetic studies in erythroleukaemia. Evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types. Brit J Haematol 1990; 75:346-354.

49. Vanni R, **Dal Cin P**, Van Den Berghe H. Is the chromosome band 1p36 another hot-spot for rearrangements in uterine leiomyoma? Genes Chromosomes Cancer 1990; 2: 255-256.

50. Paulien S, Turc-Carel C, **Dal Cin P**, Sait S, Sreekantaiah C, Leong S, Vogelstein B, Kinzler KW, Sandberg AA, Gemmill RM. Myxoid liposarcoma with t(12;16)(q13;p11) contains site-specific alterations in methylation patterns surrounding a zinc-finger gene that maps to the breakpoint region. Cancer Res 1990; 50:7902-7907.

51. Speleman F, Mangelschots K, Vercruyssen M, **Dal Cin P**, Aventin A, Offner F, Laureys G, Van Den Berghe H, Leroy J. Analysis of whole-arm translocations in malignant hematologic cells by non-isotopic *in situ* hybridization. Cytogenet Cell Genet 1991; 56:14-17.

52. **Dal Cin P**, Brosens I, Van Den Berghe H. Involvement of 6p in an endometrial polyp. Cancer

Genet Cytogenet 1991; 51:279-280.

53. Corallini A, Gianni M, Mantovani C, Vandini A, Rimessi P, Negrini M, Giavazzi R, Bani MR, Milanesi G, **Dal Cin P**, Van Den Berghe H, Barbanti-Brodano G. Transformation of human cells by recombinant DNA molecules containing BK virus early region and the human activated c-h-ras or c-myc oncogenes. Cancer J 1991; 4: 24-34.

54. **Dal Cin P**, De Wever I, Aerts R, Van Damme B, Van Den Berghe H. Trisomy 8 as the only chromosome change in an epithelioid smooth muscle tumor. Genes Chromosomes Cancer 1991; 3: 235-237.

55. **Dal Cin P**, Brock P, Casteels-Van Daele M, De Wever I, Van Damme B, Van Den Berghe H. Cytogenetic characterization of congenital or infantile fibrosarcoma. Eur J Pediatr 1991; 150: 579-581.

56. Speleman F, **Dal Cin P**, Van Roy N, Van Marck E, Buytaert Ph, Van Den Berghe H, Leroy JG. Is t(6;20)(p21;q13) a characteristic chromosome change in endometrial polyps? Genes Chromosomes Cancer 1991; 3: 318-319.

57. Stern C, Kazmierczak B, Thode B, Rommel B, Bartnitzke B, **Dal Cin P**, Van De Ven W, Van Den Berghe H, Bullerdiek J. Short communication. Leiomyoma cells with 12q15 aberrations can be transformed in vitro and show a relatively stable karyotype during precrisis period. Cancer Genet Cytogenet 1991; 54: 223-228.

58. Cuneo A, Carli MG, Piva N, Fagioli F, Castoldi G, **Dal Cin P**, Van Den Berghe E, Van Den Berghe H. Clinicopathological evolution and multilineage in erythroleukaemia. Report of a case. Haematologica 1991; 76: 235-237.

59. Van Den Berghe E, De Wolf-Peeters C, Louwagie A, Thomas J, Wlodarska I, **Dal Cin P**, Stul M, Cassiman JJ, Mecucci C, Van Den Berghe H. Chromosome 1p abnormalities in B non-Hodgkin lymphoma. Leuk Lymph 1991; 5:193-199.

60. **Dal Cin P**, De Wever I, Moerman Ph, Van Den Berghe H. Translocation X;12 in mesothelioma. Cancer Genet Cytogenet 1991; 55: 115-118.

61. **Dal Cin P**, Brock P, Aly MS, Casteels-Van Daele M, De Wever I, Van Damme B, Van Den Berghe H. A variant 2;13 translocation in rhabdomyosarcoma. Cancer Genet Cytogenet 1991; 55:191-195.

62. **Dal Cin P**, Van Gool S, Brock P, Proesmans W, Casteels-Van Daele M, De Wever I, Baert L, Van Damme B, Van Den Berghe H. Renal cell carcinoma in a child. Cancer Genet Cytogenet 1991; 53:137-138.

63. Rege-Cambrin G, Speleman F, Kerim S, Scaravaglio P, Carozzi F, **Dal Cin P**, Michaux JL, offner F, Saglio G, Van Den Berghe H. Extra translocation (1q9p) is a prognostic indicator in myeloproliferative disorders. Leukemia 1991; 5: 1059-1063.

64. Meltzer PS, Jankowski SA, **Dal Cin P**, Sandberg AA, Paz IB, Coccia MA. Identification and

cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 12 frequently rearranged in soft tissue tumors. Cell Growth Differ 1991; 2: 495-501.

65. **Dal Cin P**, Aly MS, De Wever I, Van Damme B, Van Den Berghe H. Does chromosome investigation discriminate between benign and malignant gastrointestinal leiomyomatous tumors? Diag Oncol 1992; 2:55-59.

66. Foschini MP, Van Eyken P, Brock PR, Casteels-Van Daele M, De Vos R, **Dal Cin P**, Van Den Berghe H, Desmet VJ. Malignant rhabdoid tumour of the liver. Histopathology 1992; 20:157-165.

67. Cuneo A, Michaux JL, Ferrant A, Van Hove L, Bosly A, Stul M, **Dal Cin P**, Van Den Berghe E, Cassiman JJ, Negrini M, Piva N, Castoldi G, Van Den Berghe H. Correlation of cytogenetic patterns and clinico-biological features in adult acute myeloid leukemia expressing lymphoid markers. Blood 1992; 79:720-727.

68. **Dal Cin P**, Sneyers W, Aly MS, Segers A, Ostijn F, Van Damme B, Van Den Berghe H. Involvement of 19q13 in follicular thyroid adenoma. Cancer Genet Cytogenet 1992; 60:99-101.

69. **Dal Cin P**, Rao U, Sait S, Karakousis C, Sandberg AA. Chromosomes in the diagnosis of soft tissue tumors. I. Synovial sarcoma. Modern Pathol 1992; 5:357-362.

70. **Dal Cin P**, Moerman Ph, De Wever I, Van Den Berghe H. Numerical chromosome aberrations in fibrothecoma. Tumori 1992; 78:140-142.

71. **Dal Cin P**, Van Damme B, Hoogmartens M, Van Den Berghe H. Chromosome changes in a case of hibernoma. Genes Chromosomes Cancer 1992; 5:178-180.

72. **Dal Cin P**, De Wolf F, Klerckx P, Van Den Berghe H. The 6p21 chromosome region is non randomly involved in endometrial polyps. Gynecol Oncol 1992; 46: 393-396.

73. **Dal Cin P**, Aly MS, Delabie J, Ceuppens JL, Van Gool S, Van Damme B, Baert L, Van Poppel H, Van Den Berghe H. Trisomy 7 and trisomy 10 characterize subpopulations of tumor-infiltrating lymphocytes in kidney tumors and in the surrounding kidney tissue. Proc Natl Acad Sci USA 1992; 89:9744-9748.

74. **Dal Cin P**, Aly MS, De Wever I, Moerman PH, Van Den Berghe H. Endometrial stroma sarcoma. t(7;17)(p15-21;q12-21) is a non-random chromosome change. Cancer Genet Cytogenet 1992; 63:43-46.

75. Cuneo A, Castoldi G, Michaux JL, Ferrant A, Bosly A, Boogaerts M, **Dal Cin P**, Van Den Berghe H. Adult acute myeloid leukemia. Blood 1992; 80: 1369-1370.

76. Aly MS, **Dal Cin P**, Moerman PH, De Wever I, Devriendt K, Brock P, Casteels-Van Daele M, Van Den Berghe H. Loss of the Y-chromosome in a malignant sertoli tumor. Cancer Genet Cytogenet 1993; 65:104-106.

77. **Dal Cin P**, De Wolf-Peeters C, Aly MS, Deneffe G, Van Mieghem W, Van Den Berghe H. Ring chromosome 6 as the only change in thymoma. Genes Chromosomes Cancer 1993; 6:243-244.

78. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Bosly A, Doyen CM, Carli MG, Piva N, Castoldi G, Stul M, **Dal Cin P**, Cassiman JJ, Van Den Berghe H. Clinical review on features and cytogenetic patterns in adult acute myeloid leukemia with lymphoid markers. Leuk Lymph 1993; 9:285-291.

79. Vanni R, **Dal Cin P**, Marras S, Moerman PH, Andria M, Valdes E, Deprest J, Van Den Berghe H. Endometrial polyp. Another benign tumor characterized by 12q13-15 changes. Cancer Genet Cytogenet 1993; 68:32-33.

80. **Dal Cin P**, Kools P, Sciot R, De Wever I, Van Damme B, Van De Ven W, Van Den Berghe H. Cytogenetic and FISH investigation of ring chromosomes characterizing a specific pathological subgroup of adipose tissue tumors. Cancer Genet Cytogenet 1993; 68:85-90.

81. **Dal Cin P**, Kools P, De Jonge I, Moerman PH, Van De Ven W, Van Den Berghe H. Rearrangement of 12q14-15 in pulmonary chondroid hamartoma. Genes Chromosomes Cancer 1993; 8:132-133.

82. Sciot R, **Dal Cin P**, De Vos R, Van Damme B, De Wever I, Van Den Berghe H, Desmet V. Alveolar soft part sarcoma. Evidence for its myogenic origin and for the involvement of 17q25. Histopathology, 1993; 23: 439-444.

83. **Dal Cin P**, Sciot R, Fossion E, Van Damme B, Van Den Berghe H. Chromosome abnormalities in cementifying fibroma. Cancer Genet Cytogenet 1993; 71:170-172.

84. Aly MS, **Dal Cin P**, Van De Voorde W, Van Poppel H, Ameye F, Baert L, Van Den Berghe H. Chromosome abnormalities in benign prostatic hyperplasia. Genes Chromosomes Cancer 1994; 9:227-233.

85. Schoenmakers EFPM, Kools PFJ, Mols R, Kazmierczak B, Bartnitzke S, Bullerdiek J, **Dal Cin P**, Van Den Berghe H, Van De Ven W. Physical mapping of chromosome 12q breakpoints in lipoma, pleomorphic salivary gland adenoma, uterine leiomyoma, and myxoid liposarcoma. Genomics 1995; 20:210-222.

86. Aly MS, **Dal Cin P**, Jiskoot P, Deneffe G, Marynen P, Van Den Berghe H. Competitive *in situ* hybridization in a mediastinal germ cell tumor. Cancer Genet Cytogent 1994; 73: 53-56.

87. **Dal Cin P**, Sciot R, Aly MS, Stas M, De Wever I, Van Damme B, Van Den Berghe H. Some desmoid tumors are characterized by trisomy 8. Genes Chromosomes Cancer 1994; 10:131-135.

88. **Dal Cin P**, Sciot, R, Samson I, De Smet L, De Wever I, Van Damme B, Van Den Berghe H. Cytogenetic characterization of tenosynovial giant cell tumors (nodular tenosynovitis). Cancer Res 1994; 54:3986-3987.

89. Cuneo A, Demuynck H, Ferrant A, Louwagie A, Doyen C, Stul M, Cassiman JJ, **Dal Cin P**, Negrini M, Carli MG, Boogaerts M, Michaux JL, Castoldi G, Van Den Berghe H. Minor

myeloid component in Ph-chromosome-positive acute lymphoblastic leukaemia. Correlation with cytogenetic pattern and implication for poor response to therapy. Brit J Haematol 1994; 87:515-522.

90. Sciot R, **Dal Cin P**, Brock P, Moerman PH, Van Damme B, De Wever I, Casteels-Van Daele M, Van Den Berghe H, Desmet V. Pleuropulmonary blastoma (pulmonary blastoma of childhood). Genetic link with other embryonal malignancies? Histopathology 1994; 24: 559-563.

91. **Dal Cin P**, Sciot R, Speleman F, Samson I, Laureys G, De Potter C, Meire F, Van Damme B, Van Den Berghe H. Chromosome aberrations in fibrous dysplasia. Cancer Genet Cytogenet 1994; 77:114-117.

92. **Dal Cin P**, Sciot R, De Wever I, Van Damme B, Van Den Berghe H. New discriminative chromosomal marker in adipose tissue tumors. The chromosome 8q11-q13 region in lipoblastoma. Cancer Genet Cytogenet 1994; 78:2 32-35.

93. Knight JC, Renwick PJ, **Dal Cin P**, Van Den Berghe H, Fletcher CDM. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma. Molecular and cytogenetic analysis. Cancer Res 1995; 55:24-27.

94. **Dal Cin P**, Sciot R, Van Damme B, De Wever I, Van Den Berghe H. Trisomy 20 characterizes a second group of desmoid tumors. Cancer Genet Cytogenet 1995; 79:189.

95. **Dal Cin P**, Vanni R, Marras S, Moerman PH, Kools P, Andria M, Valdes E, Deprest J, Van De Ven W, Van Den Berghe H. Four cytogenetic subgroups can be identified in endometrial polyps. Cancer Res 1995; 55:1565-1568.

96. Renwick PJ, Reeves BR, **Dal Cin P**, Fletcher CDM, Kempski H, Sciot R, Kazmierczak B, Jani K, Sonobe H, Knight JC. Two categories of synovial sarcoma defined by divergent chromosome translocation breakpoints in Xp11.2, with implications for the histologic sub-classification of synovial sarcoma. Cytogenet Cell Genet 1995; 70:58-63.

97. Uyttebroeck A, Brock P, De Groote B, Renard M, **Dal Cin P**, Van Den Berghe H, Casteels-Van Daele M. A child with the 5q- syndrome. Cancer Genet Cytogenet 1995; 80:121-123.

98. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Van Orshoven A, Criel A, Stul M, **Dal Cin P**, Hernandez J, Chatelain B, Doyen C, Louwagie A, Castoldi G, Cassiman JJ, Van Den Berghe H. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia. Correlation with clinicobiological findings. Blood 1995; 85:3688-3694.

99. **Dal Cin P**, Moerman Ph, Deprest J, Brosens I, Van Den Berghe H. A new cytogenetic subgroup in uterine leiomyoma is characterized by a deletion of the long arm of chromosome 3. Genes Chromosomes Cancer 1995; 13: 219-220.

100. Sciot R, Samson I, **Dal Cin P**, Lateur L, Van Damme B, Van Den Berghe H, Desmet V. Giant cell rich parosteal osteosarcoma. Histopathology 1995; 27:51-55.

101. Sciot R, De Vos R, **Dal Cin P**. Morfologische, immunohistochemische en cytogenetische studie

van gastro-intestinale stromale tumoren. Tijdschr Gastroenterol. Nieuwsbrief Augustus 1995;7-10.

102. Sciot R, **Dal Cin P**, Fletcher CDM, Samson I, Smith M, De Vos R, Van Damme B, Van Den Berghe H. t(9;22)(q22-31;q11-12) Is a consistent marker of extraskeletal myxoid chondrosarcoma. Evaluation of 3 cases. Mod Pathol 1995; 8:765-768.

103. **Dal Cin P**, Moerman Ph, De Wever I, Van Den Berghe H. Is i(1)(q10) a chromosome marker in phyllodes tumor of the breast? Cancer Genet Cytogenet 1995; 83:174-175.

104. Sciot R, **Dal Cin P**, Fletcher C, De Wever I, De Vos R, Van Damme B, Van Den Berghe H. Monosomy of chromosome 22 in a malignant peripheral nerve sheath tumor of the kidney. Genetic link with other malignant renal neoplasms of childhood? Histopathology 1995; 2:373-376.

105. Dei Tos AP, Calonje E, Sciot R, Pauwels P, Knight JC, **Dal Cin P**, Fletcher CDM. Immunohistochemical demonstration of glycoprotein P30/32^{MIC2} (CD99) in synovial sarcoma. A potential cause of diagnostic confusion. App Immunhistochem 1995;3: 168-173.

106. **Dal Cin P**, Sciot R, De Wever I, Brock P, Casteels-Van Daele M, Van Damme B, Van Den Berghe H. Cytogenetic and immunohistochemical evidence that giant cell fibroblastomai related to dermatofibrosarcoma protuberans. Genes Chromosomes Cancer 1996; 15:73-75.

107. Fletcher CMD, Akerman M, **Dal Cin P**, De Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Van De Ven W, Vanni R, Willen H. Correlation between clinicopathologic features and karyotype in lipomatous tumors. A report of 178 cases from the chromosomes and morphology (CHAMP) collaborative study group. Am J Pathol 1996; 148:623-630.

108. **Dal Cin P**, Sciot R, Fletcher CDM, Hilliker C, De Wever I, Van Damme B, Van Den Berghe H. Trisomy 21 in solitary fibrous tumor. Cancer Genet Cytogenet 1996; 86:58-60.

109. García JL, Hernández JM, **Dal Cin P**, Ríos A, San Miguel JF, Van Den Berghe H. Translocation (15;17)(q22;q21) in a patient with Klinefeflter syndrome. Cancer Genet Cytogenet 1996; 86:86.

110. Wanschura S, Belge G, Stenman G, Kools P, **Dal Cin P**, Van Den Berghe H, Schoenmakers E, Huysmans C, Bartnizke S, Van De Ven W, Bullerdiek J. Mapping of the translocation breakpoints of primary pleomorphic adenomas and lipomas within a common region of chromosome 12. Cancer Genet Cytogenet 1996; 86:39-45.

111. **Dal Cin P**, Sciot R, De Smet L, Van Damme B, Van Den Berghe H. A new cytogenetic subgroup in tenosynovial giant cell tumors (nodular tenosynovitis) is characterized by involvement of 16q24. Cancer Genet Cytogenet 1996; 87: 85-87.

112. Qi H, **Dal Cin P**, Van De Voorde W, Elgamal AA, Van Poppel H, Baert L, Van Den Berghe H. del(1)(q12) in adenocarcinomas of the prostate. Cancer Genet Cytogenet 1996; 87:79-81.

113. **Dal Cin P**, Moerman P, Christiaens MR, Van Den Berghe H. Observation of a deletion of the

long arm of chromosome 6 in benign fibrocystic disease of the breast constitutes a challenging problem. Genes Chromosomes Cancer 1996; 16: 68-71.

114. **Dal Cin P**, Pauwels P, Sciot R, Van Den Berghe H. Multiple chromosome rearrangements in a fibrosarcoma. Cancer Genet Cytogenet 1996; 87:176-178.

115. Pauwels P, **Dal Cin P**, Van De Moosdijk CNF, Vrints L, Sciot R, Van Den Berghe H. Cytogenetics revealing the diagnosis in a metastatic endometrial stromal sarcoma. Histopathology 1996; 29:84-87.

116. **Dal Cin P**, Sciot R, De Wever I, Van Damme B, Van Den Berghe H. Diagnosis of primary renal cell carcinoma in a left supraclavicular lymph node by chromosome analysis. J Urol 1996; 156:171-172.

117. Cuneo A, Castoldi G, Michaux JL, Ferrant A, Chatelain B, Louwagie A, Boogaerts M, **Dal Cin P**, Van Den Berghe H. Differences in the chromosomal profile of AML-M0 vs AML-M1 response. Blood 1996; 87:5381-5382.

118. **Dal Cin P**, Van Poppel H, Van Damme B, Baert L, Van Den Berghe H. Cytogenetic investigation of synchronous bilateral renal tumors. Cancer Genet Cytogenet 1996; 89:57-60.

119. **Dal Cin P**, De Wolf-Peeters C, Deneffe G, Fryns JP, Van Den Berghe H. Thymoma with a t(15;22)(p11;q11). Cancer Genet Cytogenet 1996; 89:181-183.

120. Tallini G, Akerman M, **Dal Cin P**, De Wever I, Fletcher CDM, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Van Den Berghe H, Van De Ven W, Vanni R, Willen H. Combined morphologic and karyotypic study of 28 myxoid liposarcomas. Implications for a revised morphologic typing. Am J Surg Pathol 1996; 20:1047-1055.

121. Rosai J, Akerman M, **Dal Cin P**, De Wever I, Fletcher CDM, Mandahl N, Mertens F, Mitelman F, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Van De Ven W, Vanni R, Willen H. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors. Am J Surg Pathol 1996; 20:1182-1189.

122. Brosens I, Johannisson E, **Dal Cin P**, Deprest J, Van Den Berghe H. Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal, and gonadotropin-releasing hormone agonist-treated females. Fert Steril 1996; 66:376-379.

123. Mandahl N, Åkerman M, Aman P, **Dal Cin P**, De Wever I, Fletcher CDM, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Van De Ven W, Vanni R, Willen H. Duplication of chromosome segment 12q15-24 is associated with atypical lipomatous tumors. A report of the champ collaborative study group. Int J Cancer 1996; 67:632-635.

124. **Dal Cin P**, Van Poppel H, Sciot R, De Vos R, Van Damme B, Baert L, Van Den Berghe H. t(1;12)(p36;q13) in a renal oncocytoma.Genes Chromosomes Cancer 1996;17:136-139.

125. **Dal Cin P**, Marynen P, Moerman PH, Vergote I, Van Den Berghe H. Ovarian germ cell tumor

with chromosome 12 anomaly but without i(12p). Cancer Genet Cytogenet 1996; 91:61-64.

126. Cuneo A, Ferrant A, Michaux JL, Bosly A, Chatelain B, Stul M, **Dal Cin P**, Dierlamm J, Cassiman JJ, Hossfeld DK, Castoldi G, Van Den Berghe H. Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype. Study of nine cases. Cancer Genet Cytogenet 1996; 92:31-36.

127. Cuneo A, Ferrant A, Michaux JL, Demuynck H, Boogaerts M, Louwagie A, Doyen C, Stul M, Cassiman JJ, **Dal Cin P**, Castoldi G, Van Den Berghe H. Philadelphia chromosome-positive acute myeloid leukemia. Cytoimmunologic and cytogenetic features. Hematologica 1996; 81:423-427.

128. Qi H, **Dal Cin P**, Hernández J, Garcia JL, Sciot R, Fletcher C, Van Eyken P, De Wever I, Van Den Berghe H. Trisomies 8 and 20 in desmoid tumors. Cancer Genet Cytogenet 1996; 92:147-149.

129. Hernández J M, Schoenmakers EFPM, **Dal Cin P**, Michaux L, Van De Ven WJM, Van Den Berghe H. Molecular delineation of the commonly deleted segment in mature B-cell lymphoid neoplasias with deletion of 7q. Genes Chromosomes Cancer 1997; 18:147-150.

130. Vanni R, Marras S, Schoenmakers EFPM, **Dal Cin P**, Kazmierczak B, Senger G, Bullerdiek J, Van De Ven WJM, Van Den Berghe H. Molecular cytogenetic characterization of del(7q) in two uterine leiomyoma derived cell lines. Genes Chromosomes Cancer 1997; 18:155-161.

131. Wanschura S, **Dal Cin P**, Kazmierczak B, Bartnitzke S, Van Den Berghe H, Bullerdiek J. Hidden paracentric inversions of chromosome 12q affecting the HMGI-C gene. Genes Chromosomes Cancer 1997; 18:322-330.

132. **Dal Cin P**, Qi H, Sciot R, Van Den Berghe H. Involvement of chromosomes 6 and 11 in a soft tissue chondroma. Cancer Genet Cytogenet 1997; 93:177-178.

133. Van Den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B, **Dal Cin P**, Van Den Berghe H, Ceuppens JL. Identification of an enriched $CD4^+$ $CD8\alpha^{++}$ $CD8\beta^+$ T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma. Int J Cancer 1997; 71:178-182.

134. Sciot R, Akerman M, **Dal Cin P**, De Wever I, Fletcher CDM, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Tallini G, Van Den Berghe H, Vanni R, Willen H. Cytogenetic analysis of subcutaneous angiolipoma. Further evidence supporting its difference from ordinary pure lipomas. a report of the CHAMP study group. Am J Surg Pathol 1997; 21:441-444.

135. Tallini G, **Dal Cin P**, Rhoden KJ, Chiapetta G, Manfioletti G, Giancotti V, Fusco A, Van Den Berghe H, Sciot R. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors. Immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol 1997; 151:37-43.

136. **Dal Cin P**, Sciot R, De Wever I, Van Den Berghe, H. Deletion of the long arm of chromosome 7 in lipoma. Cancer Genet Cytogenet 1997; 96: 85-86.

137. **Dal Cin P**, Sciot R, Panagopoulos I, Åman P, Samson I, Mandahl N, Mitelman F, Van Den Berghe H, Fletcher CDM. Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma. Clinicopathological features. J Pathol 1997; 182:437-441.

138. **Dal Cin P**, Polito P, Van Eyken P, Sciot R, Hernandez JM, Garcia JL, Van Den Berghe H. Anomalies of chromosomes 17 and 22 in giant cell fibroblastoma. Cancer Genet Cytogenet 1997; 97:165-166.

139. **Dal Cin P**, Sciot R, Polito P, Stas M, De Wever I, Cornelis A, Van Den Berghe H. Lesions of 13q may occur independently of deletion of 16q in spindle cell/pleomorphic lipomas. Histopathology 1997; 31: 222-225.

140. **Dal Cin P**, Wanschura S, Christiaens MR, Van Den Berghe I, Moerman PH, Polito P, Kazmierczak B, Bullerdiek J, Van Den Berghe H. Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGIY. Genes Chromosomes Cancer 1997; 20:90-92.

141. Sciot R, **Dal Cin P**, Fletcher CDM, Hernandez JM, Garcia JL, Samson I, Ramos L, Brys P, Van Damme B, Van Den Berghe H. Inflammatory myofibroblastic tumor of bone. Report of two cases with evidence of clonal chromosomal changes. Am J Surg Pathol 1997; 21:1166-1172.

142. **Dal Cin P**, Sciot R, Van Poppel H, Baert L, Van Damme B, Van Den Berghe H. Chromosome analysis in angiomyolipoma. Cancer Genet Cytogenet 1997; 99:132-134.

143. **Dal Cin P**, Qi H, Pauwels P, Backx C, Van Den Berghe H. Monosomy 22 in a fibrothecoma. Cancer Genet Cytogenet 1997; 99:129-131.

144. **Dal Cin P**, Dei Tos AP, Qi H, Giannini C, Furlanetto A, Longatti PL, Marynen P, Van Den Berghe H. Immature teratoma of the pineal gland with isochromosome 12p. Acta Neuropathol 1998; 95: 107-110.

145. **Dal Cin P**, Stas M, Sciot R, De Wever I, Van Damme B, Van Den Berghe H. Translocation X;1 reveals metastasis after 31 years of renal cell carcinoma. Cancer Genet Cytogenet 1998; 101:58-61.

146. Kazmierczak B, **Dal Cin P**, Wanschura S, Bartnitzke S, Van Den Berghe H, Bullerdiek J. Cloning and molecular characterization of part of a new gene fused to HMGIC in mesenchymal tumors with inv(12)(p11.2q15). Am J Pathol 1998; 152:431-435.

147. **Dal Cin P**, Pauwels, P, Van Den Berghe H. Fibrosarcoma versus cellular fibroma of the ovary. Am J Surg Pathol 1998; 22:508-510.

148. Brosens I, Deprest J, **Dal Cin P**, Van Den Berghe H. Clinical significance of cytogenetic abnormalities in uterine myoma. Fertil Steril 1998; 69:232-305.

149. **Dal Cin P**, Moerman Ph, Pauwels P, Qi H, Van Den Berghe H. Hyperdiploidy in benign breast lesions. Cancer Genet Cytogenet 1998; 101:162-163.

150. Willén H, Åkerman M, **Dal Cin P**, De Wever I, Fletcher CDM, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni, R. Comparison of chromosomal pattern with clinical features in 165 lipomas. A report of the CHAMP study group. Cancer Genet Cytogenet 1998; 102: 46-49.

151. Buonamici L, Roncaroli F, **Dal Cin P**, Van Den Berghe H, Frank G, Calbucci F, Eusebi V. Cytogenetic analysis of pituitary adenomas. A study of 9 cases and review of the literature. Pathologica 1998; 90:116-119.

152. Mertens F, Fletcher CDM, **Dal Cin P**, De Wever I, Mandahl N, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willén H. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features. A report of the CHAMP study group. Genes Chromosomes Cancer 1998; 22:16-25.

153. **Dal Cin P**, Wanschura S, Kazmierczak B, Tallini G, Dei Tos AP, Bullerdiek J, Van Den Berghe I, Moerman PH, Van Den Berghe H. Amplification and expresssion of the HMGIC gene in a benign endometrial polyp. Genes Chromosomes Cancer 1998; 22: 95-99.

154. **Dal Cin P**, Lipcsei G, Hermand G, Boniver J, Van Den Berghe H. Congenital mesoblastic nephroma and trisomy 11. Cancer Genet Cytogenet 1998; 103: 68-70.

155. **Dal Cin P**, Sciot R, Fletcher CDM, Samson I, De Vos R, Mandahl N, Willén H, Larson O, Van Den Berghe H. Inflammatory leiomyosarcoma may be characterized by specific near-haploid chromosome changes. J Pathol 1998; 185:112-115.

156. **Dal Cin P**, Sciot R, De Smet L, Van Den Berghe H. Translocation 2;11 in a fibroma of tendon sheath. Histopathology 1998; 32:433-435.

157. **Dal Cin P**, Timmerman D, Van Den Berghe I, Wanschura S, Kazmierczak B, Vergote I, Deprest J, Neven P, Moerman Ph, Bullerdiek J, Van Den Berghe H. Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. Cancer Res 1998; 58: 2278-2281.

158. Kazmierczak B, **Dal Cin P**, Wanschura S, Borrmann L, Fusco A, Van Den Berghe H, Bullerdiek J. HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes Chromosomes Cancer 1998; 23:279-285.

159. Balzarini P, **Dal Cin P**, Roskams T, Polito P, Van Poppel H, Van Damme B, Baert L, Van Den Berghe H. Histology may be dependent upon the presence of partial monosomy or partial trisomy 3 in renal cell carcinoma. Cancer Genet Cytogenet 1998; 105:6-10.

160. Polito P, **Dal Cin P**, Pauwels P, Christiaens MR, Van Den Berghe I, Moerman P, Vrints L, Van Den Berghe H. An important subgroup of phyllodes tumors of the breast is characterized by rearrangements of chromosomes 1q and 10q. Oncol Rep 1998; 5:1099-1102.

161. **Dal Cin P**, Sciot R, Samson I, De Wever I, Van Den Berghe H. Osteoid osteoma and osteoblastoma with clonal chromosome changes. Br J Cancer 1998; 78:344-348.

162. Sciot R, **Dal Cin P**, Bellemans J, Samson I, Van Den Berghe H, Van Damme B. Synovial chondromatosis. Clonal chromosome changes provide further evidence for a neoplastic disorder. Virchows Arch 1998; 433:189-191.

163. O'Brien KP, Seroussi E, **Dal Cin P**, Sciot R, Mandahl N, Fletcher JA, Turc-Carel C, Dumanski JP. Various regions within the alpha helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998; 23:187-193.

164. **Dal Cin P**, Gutierrez NC, Hernandez JM, Van Den Berghe H. Molecular cytogenetics in angiomyolipomas. Cancer Genet Cytogenet 1998; 106:182.

165. Polito P, **Dal Cin P**, Kazmierczak B, Rogalla P, Bullerdiek J, Van Den Berghe H. Deletion of HMG17 in uterine leiomyomas with ring chromosome 1. Cancer Genet Cytogenet 1998; 108:107-109.

166. Losi L, Polito P, Hagemeijer A, Buonamici L, Van Den Berghe H, **Dal Cin P**. Intracranial germ cell tumour with complex karyotype including isochromosome 12p. Virchows Arch 1998; 433:571-574.

167. Pedeutour F, Quade BJ, Weremowicz S, **Dal Cin P**, Ali S, Morton CC. Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata. Genes Chromosomes Cancer 1998; 23:361-366.

168. Dei Tos AP, **Dal Cin P**, Sciot R, Furlanetto A, Da Mosto MC, Giannini C, Ferlito A. Synovial sarcoma of the larynx and the hypopharynx. Clinicopathologic and cytogenetic analysis of two cases. Ann Otorhinol Laryn 1998; 107:1080-1085.

169. **Dal Cin P**, De Smet L, Sciot R, Van Damme B, Van Den Berghe H. Trisomy 7 and Trisomy 8 in dividing and non dividing tumor cells in Dupuytren's disease. Cancer Genet Cytogenet 1999; 108:137-140.

170. Buonamici L, Roncaroli F, **Dal Cin P**, Losi L, Van Den Berghe H, Calbucci F. Cytogenetic investigation in subependymoma. Cancer Genet Cytogenet 1999; 108:84.

171. Kazmierczak B, **Dal Cin P**, Meyer-Bolte K, Van Den Berghe H, Bullerdiek J. HMG1 is not the target of 13q12 rearrangements in lipomas. Genes Chromosomes Cancer 1999; 24:290-292.

172. Polito P, **Dal Cin P**, Sciot R, Brock P, Van Eyken P, Van Den Berghe H. Embryonal rhabdomyosarcomas with only numerical chromosome changes. Case report and review of the literature. Cancer Genet Cytogenet 1999; 109: 161-165.

173. **Dal Cin P**, Pauwels P, Poldermans LJ, Sciot R, Van Den Berghe H. Clonal chromosome abnormalities in a so-called dupuytren's subungual exostosis. Genes Chromosomes Cancer 1999; 24:162-164.

174. **Dal Cin P**, Van Poppel H, Roskams T, Van Den Berghe H. Involvement of 12q12-13 is a

nonrandom chromosome change in renal oncocytoma. Genes Chromosomes Cancer 1999; 24:94.

175. Sciot R, **Dal Cin P**, Samson I, Van Den Berghe H, Van Damme B. Clonal chromosomal changes in juxtaarticular myxoma. Virchows Arch 1999; 434:177-180.

176. Pauwels P, Van Nes E, Sciot R, Lammens M, Penn O, **Dal Cin P**, Van Den Berghe H. Primary malignant peripheral nerve sheath tumour of the heart. Histopathology 1999; 34:56-59.

177. Pauwels P, Sciot R, **Dal Cin P**, Roumen R, Van Den Berghe H. Intramuscular mixed tumor with clonal chromosomal changes. Virchows Arch 1999; 434: 167-171.

178. **Dal Cin P**, Fusco A, Belge G, Chiappetta G, Fedele M, Pauwels P, Bullerdiek J, Van Den Berghe H. Involvement of HMGI(Y) gene in a microfollicular adenoma of the thyroid. Genes Chromosomes Cancer 1999; 24: 286-289.

179. **Dal Cin P**, Bertoni F, Bacchini P, Hagemeijer A, Van Den Berghe H. Fibrous dysplasia and the short arm of chromosome 12. Histopathology 1999; 34: 279-280.

180. Balzarini P, Grigolato P, Tardanico R, Cadei M, Cunico S, Cozzoli A, Zanotelli T, Van Den Berghe H, **Dal Cin P**. Multitechnical pathological diagnosis in chromophobe renal cell carcinoma. Oncol Rep 1999; 6: 295-299.

181. Vanni R, Marras S, Faa G, Uccheddu A, **Dal Cin P**, Sciot R, Samson I, Van Den Berghe H. Chromosome instability in elastofibroma. Cancer Genet Cytogenet 1999; 111:182-183.

182. Sciot R, **Dal Cin P**, Hagemeijer A, Desmet L, Van Damme B, Van Den Berghe H. Cutaneous sclerosing perineurioma with cryptic NF2 gene deletion. Am J Surg Pathol 1999; 23: 849-853.

183. Van Den Berghe I, **Dal Cin P**, Sciot R, Vanvuchelen J, Michielssen P, Hagemeijer A, De Baene L, Van Den Berghe H. Translocation (4;8) as a primary chromosome change in a hydropic leiomyoma. Histopathology 1999; 34: 278.

184. Sciot R, Samson I, Van Den Berghe H, Van Damme B, **Dal Cin P**. Collagenous fibroma (desmoplastic fibroblastoma): genetic link with fibroma of tendon sheath? Modern Pathol 1999; 12:565-568.

185. Gisselsson D, Höglund M, Mertens F, Johansson B, **Dal Cin P**, Van Den Berghe H, Earnshaw C, Mitelman F, Mandahl N. The structure and dynamics of ring chromosomes in human neoplastic and non-neoplastic cells. Hum Genet 1999; 104:315-325.

186. Fletcher CDM, **Dal Cin P**, De Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willen H. Correlation between clinicopathological features and karyotype in spindle cell sarcomas: a report of 133 cases from the CHAMP study group. Am J Pathol 1999; 154:1841-1847.

187. Sciot R, Rosai J, **Dal Cin P**, De Wever I, Fletcher CDM, Mandahl N, Mertens F, Mitelman F, Rydholm A, Tallini G, Van Den Berghe H, Vanni R, Willén H. Localized and diffuse tenosynovial giant cell tumor: Analysis of 35 cases. A report from the CHAMP study group.

Modern Pathol 1999; 12:576-579.

188. Gisselsson D, Höglund M, Mertens F, **Dal Cin P**, Mandahl N. Hibernomas are characterised by homozygous deletions in the multiple endocrine neoplasia type I region. Metaphase fluorescence *in situ* hybridization reveals complex rearrangements not detected by conventional cytogenetics. Am J Pathol 1999; 155:61-66.

189. **Dal Cin P**, Roskams T, Van Poppel H, Balzarini P, Van Den Berghe H. Cytogenetic investigation of transitional cell carcinomas of the upper urinary tract. Cancer Genet Cytogenet 1999; 114:117-120.

190. Balzarini P, Tardanico R, Grigolato P, Cunico S, Cozzol A, Zanotalli T, Van Den Berghe H, **Dal Cin P**. Atypical Chromosome abnormalities in a renal oncocytoma. Cancer Genet Cytogenet 1999;113: 103-104.

191. **Dal Cin P**, Pauwels P, Van Den Berghe H. Solitary Fibrous tumor of the pleura with t(4;15)(q13;q26). Histopathology 1999; 35: 94-95.

192. Kazmierczak B, **Dal Cin P**, Sciot R, Van Den Berghe H, Bullerdiek J. Inflammatory myofibroblastic tumor with HMGIC rearrangement. Cancer Genet Cytogenet 1999; 122:156-160.

193. Buonamici L, Roncaroli F, Fioravanti A, Losi L, Van Den Berghe H, Calbucci F, **Dal Cin P**. Cytogenetic investigation of chordoma of the skull. Cancer Genet Cytogenet 1999; 112: 49-52.

194. Van Den Berghe I, **Dal Cin P**, De Groef K, Michielssen P, Van Den Berghe H. Monosomy 22 and trisomy 14 may be early events in the tumorigenesis of adult granulosa cell tumor. Cancer Genet Cytogenet 1999; 112: 46-48.

195. **Dal Cin P**, Pauwels P, Van Den Berghe H. Epithelioid sarcoma of the proximal type with complex karyotype including i(8q). Cancer Genet Cytogenet 1999; 114:80-82.

196. Tallini G, **Dal Cin P**. HMGIY and HMGIC dysregulation, a common occurrence in human tumors. Adv Anat Path 1999; 6: 237-246.

197. **Dal Cin P**, Quade GJ, Weremowicz S, Morton CC, Pauwels P , Van Den Berghe H. Primary parauterine leiomyoma with a t(6;14). Genes Chromosomes Cancer 1999; 26: 383-384.

198. Tejpar S, Li C, Nollet F, Li C,Wunder JS, Michils G, **Dal Cin P**, Van Cutsem E, Bapat B, Van Roy F, Cassiman JJ, Alman BA. Predominance of beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999; 18: 615-620.

199. Mulier S, Stas M, Delabie J, Lateur L, Gysen M, **Dal Cin P**, De Wever I. Diagnosis and treatment of proliferative myositis: case report and review. Skeletal Radiol 1999; 28:703-709.

200. Losi L, Buonamici L, **Dal Cin P**, Giannini C, Dei Tos A, Calbucci F, Eusebi V. Cytogenetics of tumors of the central nervous system: case study and literature review. Pathologica 1999; 91:249-255.

201. Kazmierczak B, **Dal Cin P**, Rogalla P, Van Den Berghe H, Bullerdiek J. The possible related breakpoints in human tumors - regional fine mapping of the human HMG17 gene to chromosomal band 1p35. Cancer Genet Cytogenet 2000; 116:164-165.

202. **Dal Cin P**, Roskams T, De Vos R, Van Poppel H, Balzarini P, Van Den Berghe H. Involvement of chromosomes 1 and 18 in renal cell tumors. Cancer Genet Cytogenet 2000; 116: 54-58.

203. Pauwels P, Ambros P, Hattinger C, Lammens M, **Dal Cin P**, Ribot J, Struyk A, Van Den Berghe H. Peripheral primitive neuroectodermal tumor of the cervix. Virchows Arch 2000; 436: 68-73.

204. Mandahl N, Fletcher CDM, **Dal Cin P**, De Wever I, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willén H. Comparative cytogenetic study of spindle cell and pleomorphic soft tissue leiomyosarcomas. A report from the CHAMP study group. Cancer Genet Cytogenet 2000; 116:66-73.

205. Tallini G, Vanni R, Manfioletti G, Kazmierczak B, Pauwels P, Bullerdiek J, Giancotti V, Van Den Berghe H, **Dal Cin P**. Immunoreactivity for HMGI(Y) And HMGI-C correlates with cytogenetic abnormalities at 6p21 and 12q15 in lipomas pulmonary chondroid hamartoma, endometrial polyp and uterine leiomyoma and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest 2000; 80:359-369.

206. Mertens F, **Dal Cin P**, De Wever I, Fletcher CDM, Mandahl N, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willén H. Cytogenetic characterization of peripheral nerve sheath tumors. A report of the CHAMP group. J Pathol 2000; 190:31-38.

207. Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M, **Dal Cin P**, Maestro R, Fletcher CDM, Tallini G. Coordinated expression and amplification of the MDM2, CDK4 and HMGIC genes in atypical lipomatous tumors. J Pathol 2000; 190:531-536.

208. Gisselsson D, Pettersson L, Höglund M, Hiedenblad M, Gurunova L, Wiegant J, Mertens F, **Dal Cin P**, Mitelman F, Mandahl N. Chromosomal breakage-fusion-bridge events cause genetic intratumor heretogeneity. Proc Natl Acad Sci USA 2000; 97:5357-5362.

209. **Dal Cin P**, Kozakewich HP, Goumnerova L, Mankin HJ, Rosenberg AE, Fletcher JA. Variant translocations involving 16q22 and 17p13 in solid variant and extraosseous forms of aneurysmal bone cysts. Genes Chromosomes Cancer 2000; 28: 233-234.

210. Pauwels P, Sciot R, Lammens M, Croiset F, Rutten H , Van Den Berghe H, **Dal Cin P**. Myofibroblastoma of the breast; genetic link with a spindle cell lipoma. J Pathol 2000; 191: 282-285.

211. Pauwels P, **Dal Cin P**, Vlasveld LT, Aleva RM, Van Erp WFM, Jones D. A chromosomal abnormality in hyaline vascular Castelman'disease: evidence for clonal proliferation of dysplastic stromal cells. Am J Surg Pathol 2000; 24:882-888.

212. Vanni R, Fletcher CDM, Sciot R, **Dal Cin P**, De Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Tallini G, Van Den Berghe H, Willén H. Cytogenetic evidence of clonality in cutaneous benign fibrous histiocytomas: a report of the CHAMP study group. Histopathology 2000; 37:212-217.

213. De Wever I, **Dal Cin P**, Fletcher CDM, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willén H. Cytogenetic, clinical and morphologic correlations in 78 cases of fibromatosis: a report from the CHAMP study group. Modern Pathol 2000; 13:1080-1085.

214. Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BR, **Dal Cin P**, Pinkus JL, Pinkus GS, Xiao S,Yi ES, Fletcher CDM, Fletcher JA. ALK oncogenic mechanisms in inflammatory myofibroblastic tumors. Am J Pathol 2000;157:377-384.

215. Hibbard MK, Kozakewich HP, **Dal Cin P**, Sciot R, Xiao S, Fletcher JA. PLAG1 fusion oncogenes in lipoblastoma. Cancer Res 2000; 60:4869-4872.

216. **Dal Cin P**, Sciot R, Brys P, Wever I, Dorfman H, Fletcher CDM, Jonsson K, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Samson I, Tallini G, Van Den Berghe H, Vanni R, Willen H. Recurrent chromosome aberrations in fibrous dysplasia: a report of the CHAMP study group. Cancer Genet Cytogenet 2000; 122:30-32.

217. Sciot R, Dorfman H, Brys P, **Dal Cin P**, De Wever I, Fletcher CDM, Jonson K, Mandahl N, Mertens F, Mitelman F, Rosai R, Rydholm A, Samson I, Tallini G, Van Den Berghe H, Vanni R,Willén H. Cytogenetic analysis of aneurysmal bone cyst, giant cell tumor of bone and mixed lesions: a report from the CHAMP study group. Modern Pathol 2000; 13:1206-1210.

218. Van Poppel H, Nilsson S, Algaba F, Bergerheim U, **Dal Cin P**, Fleming S, Hellsten S, Kirkali Z, Klotz L, Lindblad P, Ljungberg B, Mulders P, Roskam T, Ross RK, Walker C, Wersall P. Precancerous lesion in the kidney. Scand J Urol Nephrol (Suppl 205) 2000; 136-165.

219. Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Argani P, Lieberman Ph H, Meindl A, Ueda T, Yoshikawa H, Meloni-Ehrig A, Sorensen PHB, Mitelman F, Mandahl N, Van Den Berghe H, Sciot R, **Dal Cin P**, Bridge J. The t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001; 20:48-57.

220. Gisselsson D, Björk J, Höglund M, Mertens F, **Dal Cin P**, Åkerman M, Mandahl N. Abnormal nuclear shape in tumors reflects mitotic instability. Am J Pathol 2001; 158:199-206.

221. **Dal Cin P**, Atkins L, Ford C, Ariyanayagam S, Armstrong SA, George R, Cleary A, Morton CC. Multiple copies of AML1 in childhood acute lymphoblastic leukemias. Genes Chromosomes Cancer 2001; 30:407-409.

222. Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, Van Den Berghe H, **Dal Cin P**, Fletcher JA, Sklar J. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 2001; 98:6348-6353.

223. Panagopoulos I, Mertens F, Isaksson M, Limon J, Gustafson P, Mans A, Sciot R, **Dal Cin P**, Samson I, Iliszko M, Ryoe J, Debiec-Rychter M, Szadowska A, Skytting B, Brosjo O, Larsson O, Mitelman F, Mandahl N. Molecular and cytogenetic characterization of synovial sarcoma. Genes Chromosomes Cancer 2001; 31:362-372.

224. Debiec-Rychter M, Sciot R, Pauwels P, Schoenmakers E, Dal Cin P, Hagemeijer A. Molecular cytogenetic defenition of three distinct chromosome 14q deletion intervals in gastrointestinal stromal tumors. Genes Chromosomes Cancer 2001; 32: 26-32.

225. Sjöblom T, Shimizu A, O'Brien KP, Pietras K, **Dal Cin P**, Buchdunger E, Dumanski JP, Östman A, Heldin CH. Growth inhibition of dermatofibrosarcoma protuberans tumors by the PDGF receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61: 5778-5783.

226. Gisselsson D, Hibbard MK, **Dal Cin P**, Sciot R, His BL Kozakewich HP, Fletcher JA. PLAG1 alterations in lipoblastoma: involvement of varied mesenchymal cell types and evidence for alternative oncogenic mechanisms. Am J Pathol 2001; 159:955-962.

227. Vargas SO, French CA, Faul PN, Fletcher JA, Davis IJ, **Dal Cin P**, Perez-Atayde AR. Upper respiratory tract carcinoma with chromosomal translocation 15;19: evidence for a distinct disease entity of young patients with a rapidly fatal course. Cancer 2001; 92:1195-1203.

228. Bovée JVMG, Sciot R, **Dal Cin P**, Debiec-Rychter M, Van Zelderen-Bhola SL, Cornelisse CJ, Pancras C.W. Hogendoorn PCW. Chromosome 9 alterations and trisomy 22 characterize central chondrosarcoma; a cytogenetic and DNA flowcytometric analysis of chondrosarcoma. Diagn Pathol 2001; 10:228-235.

229. Gisselsson D, Tord Jonson T, Petersén A, Strömbeck B, Mertens F, **Dal Cin P**, Höglund M, Mitelman F, Mandahl N. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumours. Proc Natl Acad Sci USA 2001; 98:12683-12688.

230. Adem C, Gisselsson D, **Dal Cin P**, Nascimento AG. Detection of ETV6 rearrangements in infantile fibrosarcomas and congenital mesoblastic nephromas by interphase fluorescence *in situ* hybridization. Modern Pathol 2001; 14:1246-1251.

231. French CA, Miyoshi I, Kubonishi I, Kroll TG, **Dal Cin P**, Vargas SO, Perez-Atayde A, Fletcher JA. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am J Pathol 2001; 159: 1987-1992.

232. Gisselsson D, Pålsson E, Höglund M, Domanski HA, Mertens F, Pandis N, Sciot R, **Dal Cin P**, Bridge JA, Mandahl N. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcomas. Genes Chromosomes Cancer 2002; 33:133-140.

233. Quade QJ, **Dal Cin P**, Neskey DM, Weremowicz S, Morton CC. Intravenous leiomyomatosis: molecular and cytogenetic analysis of a case. Modern Pathol 2002; 15:351-356.

234. Tallini G, Dorfman H, Brys P, **Dal Cin P**, De Wever I, Fletcher CDM, Jonson K, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Samson I, Sciot R, Van Den Berghe H, Vanni R, Willén H. Correlation between clinicopathologic features and karyotype in 100 cartilaginous and chordoid tumors. A report from the chromosomes and morphology (CHAMP) collaborative study group. J Pathol 2002; 196:194-203.

235. Bloomfield CD, Archer KJ, Mrózek K, Lillington DM, Kaneko Y, Head DR, **Dal Cin P**, Raimondi SC. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33: 362-378.

236. **Dal Cin P**, Sciot R, Van Poppel H, Balzarini P, Roskams t, Van Den Berghe H. Chromosome changes in sarcomatoid renal carcinomas are different from those in renal cell carcinomas. Cancer Genet Cytogenet 2002; 134:38-40.

237. Van Dorpe J, **Dal Cin P**, Weremowicz S, Fletcher CDM, De Wever I, Van Den Berghe H, Van Leuven F, Sciot S. Translocation of the HMGI-C (HMGA2) gene in a benign mesenchymoma (chondrolipoangioma). Virchows Arch 2002; 440:485-490.

238. Colwell AS, Jonathan D'Cunha J,Vargas SO, Parker B, **Dal Cin P**, Michael A, Maddaus MA.Synovial Sarcoma of the Pleura: A Clinical and pathologic study of three new cases. J Thorac Cardiov Sur 2002; 124:828-832.

239. **Dal Cin P**, Morton CC. 1q42-q44 is rarely involved cytogenetically in sporadic uterine leiomyomata. Cancer Genet Cytogenet 2002; 138:92-93.

240. Panagopoulos I, Mertens F, Isaksson M, Domansky HA, Rydholm A, Brosjo O, Heim S, Bjerkehagen B, Sciot R, **Dal Cin P**, Fletcher JA, Fletcher CDM, Mandahl N. Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer 2002; 35:340-352.

241. Mertens F, Stromberg U, Mandahl N, **Dal Cin P**, De Wever I, Fletcher CDM, Mitelman F, Rosai R, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willén H. Chromosomal aberrations associated with metastasizing soft tissue sarcoma: a report of the CHAMP study group. Cancer Res 2002; 62:3980-3984.

242. Hirsch MS, Weinstein MH Thomas A, **Dal Cin P**. Identical karyotypes in synchronous bilateral clear cell renal cell carcinomas. Cancer Genet Cytogenet 2002; 139: 86-87.

243. Nilsson M, Hoglund M, Panagopoulos I, Sciot R, **Dal Cin P**, Debiec-Rychter M, Mertens F, Mandahl N. Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors. Virchows Arch 2002; 441:475-480.

244. Varnholt H, Vauthey J-N, **Dal Cin P**, De Marsh RW, Lauwers GY. Biliary adenofibroma originates from interlobular bile duct. Am J Surg Pathol 2003; 27:693-698.

245. **Dal Cin P**, Quade BJ, Neskey DM, Kleinman MS,Weremowicz S, Morton CC. Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24). Genes Chromosomes Cancer 2003; 36:205-206.

246. Quade BJ, Weremowicz S, Nesky DM, Vanni R, Ladd C, **Dal Cin P**, Morton CC. Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res 2003; 63: 1351-1358.

247. Duensing S, Lee BH, **Dal Cin P**, Munger K. Excessive centrosome abnormalities without ongoing numerical chromosome instability in a malignant lymphoma. Molecular Cancer 2003; 2: 30-37.

248. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Laval L, Kurtin P, **Dal Cin P**, Ladd C, Feuerhake F, Aguiar R, Li S, Salles G, Berger F, Jing W, Pinkus G, Habermann T, Dalla-Favera R, Harris N, Aster JC, Golub T, Shipp M. The molecular signature of mediastinal large B-cell lymphoma differs from that of diffuse large B-cell lymphoma and shares features with classical Hodgkin's lymphoma. Blood 2003; 102: 3871-3879.

249. Pentimalli F, Dentice M, Fedele M, Pierantoni GM, Francesco Trapasso F, Cito L, Santoro M, Viglietto G, **Dal Cin P**, Fusco A. Suppression of HMGA2 protein synthesis could be a tool for therapy of well-differentiated liposarcoma overexpressing HMGA2. Cancer Res 2003; 63:7423-7427.

250. **Dal Cin P**, Sherman L, Marzelli M, Mclaughlin C, Zukerberg L, Amrein PC. A new case of t(11;17)(q23;q21) with MLL rearrangement. Cancer Genet Cytogenet 2004; 148:178-179.

251. **Dal Cin P**, Thomas A, Weremowicz S. An intragenic rearrangement of HMGA2 is not necessary to occur for lipoma formation. Cancer Genet Cytogenet 2004; 149; 178-179.

252. Joniau S, Kreuzbauer S, Bogaert G, **Dal Cin P**, Oyen R, Sciot R, Van Poppel H. Benign mesenchymoma of the kidney in infancy: a novel pathologic and karyotype entity. Urology 2004; 63: 981-984.

253. Quade BJ, Wang T-Y, Sornberger K, **Dal Cin P**, Mutter GL, Morton CC. Molecular pathogenesis of uterine smooth muscle tumors: insights from transcriptional profiling genes. Chromosomes Cancer 2004; 40:97-108.

254. Si MW, Thorson JA, Lauwers GY, **Dal Cin P**, Furman J. Hepatocellular lymphoepithelioma-like carcinoma associated with Epstein Barr Virus: a hitherto unrecognized entity. Diagnostic Mol Pathol 2004; 13:183-189.

255. Oliveira AM, Hsi BL, Weremowicz S, Perez-Atayde AR, Rosenberg AE, **Dal Cin P**, Bridge JA, Fletcher JA. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res 2004; 64:1920-1923.

256. Nascimento AF, **Dal Cin P**, Cileno BG, Perez-Atayde AR,Kozakewich HPW, Nosé V. Urachal inflammatory myofibrobalstic tumor with ALK rearrangement: a study of urachal remnants. Urol 2004; 64:140-144.

257. Moore SDP, Herrick SR, Ince TA, Kleinman MS, **Dal Cin P**, Morton CC, Quade BJ. Uterine leiomyoma with t(10;17) disrupt the histone acetyltransferase MORF. Cancer Res 2004; 64:5570-5577.

258. Wang L, Pitman MB, Fernandez-Del Castillo C, **Dal Cin P**, Oliva E. Choriocarcinoma of the pancreas as first manifestation of a metastatic regressing mixed testicular germ cell tumor. Modern Path 2004; 17:1573-1580.

259. Moore SDP, Strehl S, **Dal Cin P**. AML with t(11;17)(q23;q12-21) involves a MLL and AF17 fusion. Cancer Gen Cytogenet 2005; 157:87-89.

260. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Bingyan Wu B, Pasqualucci L, Neuberg D, Aguiar RCT, **Dal Cin P**, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma reveals discrete clusters including one characterized by host inflammatory response. Blood 2005; 105:1851-1861.

261. Christacos NC, Sherman L, Roy A, DeAngelo DJ, **Dal Cin P**. Is the cryptic interstitial deletion of 8q24 surrounding MYC a common mechanism in the formation of double minute chromosome? Cancer Genet Cytogenet 2005; 161:90-92.

262. Oliveira AM, Perez-Atayde AR, **Dal Cin P**, Gebhardt MC, Rosenberg AE, Bridge JA, Fletcher JA. Aneurysmal bone cyst variant translocations upregulate usp6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150 and OMD genes. Oncogene 2005; 24: 3419-3426.

263. Srivastava A , Nielsen GP, **Dal Cin P**, Andrew E, Rosenberg AE. Monophasic synovial sarcoma of the liver. Arch Pathol Lab Med 2005; 129:1047-1049.

264. Ligon AH, DeAngelo DJ, Atkins L, **Dal Cin P**. Isochromosome of a deleted 20q in MDS: isochromosome of a deleted 20q may be a relatively common abnormality in myeloid malignancies. Cancer Genet Cytogenet 2005; 162: 89-91.

265. Christacos NC, Quade BJ, Morton CC, **Dal Cin P**. Uterine leiomyomata with deletions of 1p represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer 2006; 45:304-312.

266. Hirsch MS, **Dal Cin P**, Fletcher CDM. ALK expression in pseudosarcomatous myofibroblastic proliferations of the genitourinary tract. Histopathology 2005; 48:569-578.

267. Rabban JT, **Dal Cin P**, Oliva E. HMGA2 rearrangement in a case of vulvar aggressive angiomyxoma. Int J Gynecol Pathol 2006; 25:403-407.

268. Moore SDP, Offor O, Ferry JA, Philip C, Amrein PC, Morton CC, **Dal Cin P**. ERG is fused to ELF4 in a case of acute myeloid leukemia with a t(X;21) (q26;q22). Leuk Res 2006; 30:1037-1042.

269. Antonescu CR, Nafa K, Segal NH, **Dal Cin P**, Ladanyi M. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res 2006; 12: 5356-5362.

270. Takahashi H, Feuerhake F, Kutok JL, Monti S, **Dal Cin P**, Neuberg D, Aster JC, Shipp MA. Fas death domain deletions and cellular FADD-like interleukin 1{beta} converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clinical Cancer Res 2006; 12: 3265-3271.

271. Rodig SJ, Healey BM, Pinkus GS, Kuo FC, Dal **Cin P**, Kutok JL. Mantle cell lymphoma arising within nodal marginal zone lymphoma: a unique presentation of two uncommon lymphoproliferative disorders. Cancer Genet Cytogenet 2006; 171:44-51.

272. Nucci MR, Harburger D, Koontz J, **Dal Cin P**, Sklar J. Molecular analysis of the JAZF1/JJAZ1 gene fusion by RT-PCR and fluorescence *in situ* hybridization in endometrial stromal neoplasms. Am J Surg Path 2007; 31:65-70.

273. McCluggage WG, Sumathi VP, Nucci MR, Hirsch M, **Dal Cin P,** Wells M, Flanagan AM, Fisher C. Ewing family of tumours involving the vulva and vagina: Report of a series of four cases. J Clin Path 2007; 60:674-680.

274. Nucci MR, Drapkin R, **Dal Cin P**, Fletcher CDM, Fletcher JA. Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications. Am J Surg Path 2007; 31:737-743.

275. Roehrl MHA, Selig MK, Nielsen GP, Dal **Cin P**, Oliva E. A renal cell carcinoma with components of both chromophobe and papillary carcinoma. Virchows Archiv 2007; 450: 93-101.

276. Soupir CP, Vergilio JA, **Dal Cin P**, Muzikansky A, Jones DM, Kantarjian H, Hasserjian RP. Philadelphia chromosome positive acute myeloid leukemia: a rare aggressive leukemia with distinct clinicopathologic features from chronic myeloid leukemia in blast crisis. Am J Clin Path 2007; 127:642-650.

277. Hana M, Rivera MN, Battena JM, Haberb DA, **Dal Cin P**, Iafrate JA. Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene. Genes Chromosomes Cancer 2007; 46: 909-913.

278. Antonescu CR, **Dal Cin P**, Nafa K, Teot LA, Surti U, Fletcher CD, Ladanyi M. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer 2007; 46:1051-1060.

279. Deng J, Carlson N, Takeyama K, **Dal Cin P**, Shipp MA, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks and predicts response to ABT-737 in lymphoma cells. Cancer Cell 2007; 12: 97-99.

280. Takeyama K, Monti S, Manis JP, **Dal Cin P**, Getz G, Beroukhim R, Aster JC, Alt FW, Golub TR, Shipp MA. Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphoma. Oncogene 2008; 27: 318-322.

281. Hodge JC, Quade BJ, Rubin MA, Stewart EA, **Dal Cin P**, Morton CC. Molecular and cytogenetic characterization of plexiform leiomyomata provide further evidence for genetic heterogeneity underlying uterine fibroids. Am J Pathol 2008; 172:1403-1410.

282. Mertz KD, Demichelis F, Sboner A, Hirsch MS, **Dal Cin P**, Struckmann K, Storz M, Scherrer S, Schmid DM, Probst-Hensch NM, Gerstein M, Moch H, Rubin MA. Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. Int J Cancer 2008; 123: 569-576.

283. Poitras J, **Dal Cin P**, Aster JC, DeAngelo DJ, Morton CC. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 2008; 47:884-889.

284. Wang W-L, Mayordomo E, Czerniak BA, Abruzzo LV, Araujo D, **Dal Cin P**, Lev D, López-Terrada D, Lazar AJF. Fluorescence *in Situ* Hybridization (FISH) as a useful ancillary diagnostic tool for extraskeletal myxoid chondrosarcomas. Modern Path 2008; 21:1303-1310.

285. Hornick JL, **Dal Cin P**, Fletcher CDM. Loss of INI1 expression is characteristic of both conventional and proximal type epithelioid sarcoma. Am J Surg Path 2009; 33: 542-550.

286. Soupir CP, Vergilio J-A, Kelly E, **Dal Cin P**, Kuter D, Hasserjian RP. Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura. Br J Hem 2009;144: 800-802.

287. Staropoli JF, Wadleigh M, **Dal Cin P**. der(1)t(1;19)(p13;p13) in the setting of myelofibrosis with JAK2 V617F. Cancer Genetics Cytogenet 2009; 191:109-110.

288. Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, **Dal Cin P**, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Hem 2009; 145: 741-748.

289. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, **Dal Cin P**, Fletcher CDM. c-Jun amplification and overexpression are oncogenic in liposarcoma but not sufficient to inhibit the adipocytic differentiation program. J Path 2009; 218: 292-300.

290. Factor RE, **Dal Cin P,** Fletcher JA, Cibas ED. Cytogenetics and FISH as adjuncts to cytology in the diagnosis of malignant mesothelioma. Cancer Cytopathol 2009; 117:247-253.

291. Chou RC, Dinarello CA, Ferry JA, **Dal Cin P**. A 36-year-old woman with recurrent high-grade fevers, hypotension and hypertriglyceridemia. Arthritis Care Res 2010; 62:128-136.

292. Sumegi J, Streblow R, Frayer RW, **Dal Cin P**, Rosenberg A, Meloni-Ehrig A, Bridge JA. Recurrent (2;2) and (2;8) translocations in Rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator (NCOA) family. Genes Chromosomes Cancer 2010; 49:224-236.

293. Yoda A, Yoda Y, Chiaretti S, Mani K, Rodig S, Brown J, Mitsiades CS, Sattler M, Kutok J, DeAngelo D, Wadleigh M, Stone R, Xiao Y, **Dal Cin P**, Piciocchi A, Griffin J, Anderson K,

Ritz J, Foa R, Aster J, Weinstock D. Functional oncogene screening identifies CRLF2 in B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010; 107: 252-257.

294. Snuderl M, Kolman OK, Chen Y-B, Hsu JJ, Ackerman AM, **Dal Cin P**, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR. B-cell Lymphomas with concurrent *IGH-BCL2* and *MYC* rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Path 2010; 34:327-340.

295. Guardiola MT, Dobin SM, **Dal Cin P**, Donner LR. Pericentric inversion (12) (p12q13-14) as the sole chromosomal abnormality in a leiomyoma of the vulva. Cancer Genet Cytogenet 2010; 199: 21-23.

296. Medeiros F, Araujo AR, Erickson-Johnson MR, Kashyap PC, **Dal Cin P**, Nucci M, Wang X, Bell DA, Oliveira AM. *HMGA1* and *HMGA2* rearrangements in mass-forming endometriosis. Genes Chromosomes Cancer 2010; 49:630-634.

297. Roh MH, **Dal Cin P**, Silverman SG, Cibas ES. The application of cytogenetics and fluorescence *in situ* hybridization to fine needle aspiration in the diagnosis and subclassification of renal neoplasms. Cancer Cytopathol 2010;118:137-145.

298. Huang D, Sumegi J, **Dal Cin P,** Reith JD, Yasuda T, Nelson M, Muirhead D, Bridge JA. *C11orf95-MKL2* is the resulting fusion oncogene of t(11;16)(q13;p13) in chondroid lipoma. Genes Chromosomes Cancer 2010; 49:810-818.

299. Mariño-Enríquez A, Fletcher CDM, **Dal Cin P**, Hornick JL. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. Am J Surg Path 2010; 34:1122-1131.

300. Romeo S, Duim RAJ, Bridge JA, Mertens F, De Jong D, **Dal Cin P**, Wijers-Koster PM, Debiec-Rychter M, Sciot R, Rosenberg A, Szuhai K , Hogendoorn PCW. Heterogeneous and complex rearrangements of chromosome arm 6q in chondromyxoid fibroma: delineation of breakpoints and analysis of candidate target genes. Am J Path 2010; 177:1365-1376.

301. Antonescu CR, Zhang L, Chang N, Pawel BR, Travis W, Rosenberg AE, Nielsen GP, **Dal Cin P**, Fletcher CD. Novel *EWSR1-POU5F1* fusion in soft tissue myoepithelial tumors. A molecular analysis of 66 cases, including soft tissue, bone and visceral lesions, showing common involvement of *EWSR1* gene rearrangement.Genes Chromosomes Cancer 2010; 49:1114-1124.

302. Ordulu Z, **Dal Cin P**, Chong WWS, Choy KW, Lee C, Muto MG, Quade BJ, Morton CC. Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. Genes Chromosomes Cancer 2010; 49: 1152-1160.

303. Butrynski JE, D'Adamo DR, Hornick JL, **Dal Cin P**, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Janne PA, Maki RG, Demetri GD, Shapiro GI. Crizotinib in *ALK*-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363: 1727-1733.

304. Kelly PJ, Weiss SE, Sher DJ, Perez-Atayde A, **Dal Cin P**, Choueiri T. Sunitinib-Induced "Pseudo-progression" following whole brain radiotherapy for metastatic renal cell carcinoma. J Clin Oncol 2010; 28:e433-435.

305. Elco CP, Mariño-Enríquez A, Abraham JA, **Dal Cin P**, Hornick JL. Hybrid JL. Hybrid hemosiderotic fibrolipomatous tumor/ myxoinflammatory fibroblastic sarcoma: report of a case providing histologic and cytogenetic evidence for a pathogenic link between these tumor types. Am J Surg Path 2010; 34:1723-1727.

306. Choueiri TK, Lim ZD , Hirsch MS, Tamboli P , Jonasch E , McDermott DF **, Dal Cin P**, Corn P, Vaishampayan U , Heng DYC , Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010; 116:5219-5225.

307. Smoley SA , Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, **Dal Cin P**, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW. Standardization of FISH Studies on Chronic Lymphocytic Leukemia (CLL) Blood and Marrow Cells by the CLL Research Consortium. Cancer Genet Cytogenet 2010; 203: 141-148.

308. Heerema NA, Byrd JC, **Dal Cin P**, Dell' Aquila ML, Koduru P, Aviram A, Smoley S, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke D. Stimulation of chronic lymphocytic leukemia (CLL) cells with CpG oligodeoxynucleotide (ODN) gives consistent karyotypic results among laboratories: a CLL research consortium (CRC) study. Cancer Genet Cytogenet 2010; 203:134-140.

309. Roper N, Deangelo D, Kuo F, **Dal Cin P**, Ghobrial I, Aster JC. An asymptomatic 61-year-old man with *BCR-ABL*-positive bone marrow following autologous transplantation for multiple myeloma. Am J Hematol 2010; 85:944-946.

310. McDonald AG, **Dal Cin P**, Ganguly A, Campbell S, Imai Y, Rosenberg AE, Oliva E. Liposarcoma in uterine lipoleiomyoma: a report of three cases and review of the literature. Am J Surg Path 2011; 35:221-227.

311. Liang CW, Mariño-Enríquez A, Johannessen C, Hornick JL, **Dal Cin P**. Translocation (Y;12) in lipoma. Cancer Genet 2011; 204:53-56.

312. Poitras JL, Costa D, Kluk MJ, Amrein PC, Stone RM, Lee C, **Dal Cin P**, Morton CC. Genomic alterations in myeloid neoplasms with novel apparently balanced translocations**.** Cancer Genet 2011; 204: 68-76.

313. Doyle LA, Moller E, **Dal Cin P**, Fletcher CDM, Mertens F, Hornick JL. *MUC4* is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Path 2011; 35:733-741.

314. Gibson SE, Swerdlow SH, Ferry JA, Surti U, **Dal Cin P**, Harris N, Hasserjian RP. Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica. 2011; 96:1144-1152.

315. Leon A, Staropoli JF, Longtine JA, Kuo FC, **Dal Cin P**. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation. Leuk Res 2011; 35: 1188-1192.

316. Mosquera JM, **Dal Cin P**, Mertz KD, Perner S, Davis IJ, Fisher DE, Rubin MA, Hirsch MS. Validation of a TFE3 break-apart FISH assay in Xp11.2 translocation renal cell carcinoma. Diagn Mol Pathol 2011; 20:129–137.

317. Antonescu CR, Zhang L, Nielsen P, Rosenberg A, **Dal Cin P**, Fletcher CD. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosome Cancer 2011; 50:757-764.

318. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N,. Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, **Dal Cin P**, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011; 477:340-343.

319. Wang L, Motoi T, Khanin R, Socci N, Olshen A, Mertens F, Bridge J, **Dal Cin P**, Rushing EJ, Fanburg-Smith J, Antonescu C, Hameed M, Ladanyi M. Identification of a novel, recurrent *HEY1-NCOA2* fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosome Cancer. 2012, 51:127-139.

320. Armand P, Kim HT, Zhang M-J, Perez WS, **Dal Cin P**, Klumpp TR, Lazarus HM, Artz AS, Gupta V, Isola LM, Halter J, Cutler CS, Rowe JM, Antin JH, Camitta BM, Cairo MS, Sierra J, Stiff PJ, Nabhan C, Jakubowski AA, Devine SM, Maziarz RT, Marks DI, Soiffer RJ, Weisdorf DJ. Classifying cytogenetics in patients with AML in complete remission undergoing allogeneic transplantation: a CIBMTR study. Biol Blood Marrow Transplant. 2012; 18:280-288.

321. Lee CH, Ou W, Marino-Enriquez A, Zhu M, Myeda M, Wang YX, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, Gilks CB, Yaffe MB, Prentice LM, McPherson A, Jones SJM, Marra MA, Shah SP, van de Rijn M, Huntsman D, **Dal Cin P**, Debiec-Rychter M, Nucci M, Fletcher JA. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A 2012; 109: 929-934.

322. Lee CH, Mariño-Enriquez A , Ou W , Zhu M , Ali RH , Chiang S , Amant F , Rosenberg A, Oliva E , Gilks B , van de Rijn M , Debiec-Rychter M , **Dal Cin P** , Fletcher JA , Nucci MR. The clinicopathologic features of endometrial stromal sarcomas characterized by *YWHAE* rearrangement – a histologically high-grade and clinically aggressive disease. Am J Surg Path 2012; 36:641-53.

323. Kluk MJ, Chapuy B, Sinha P, Roy A, **Dal Cin P**, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012; 7:e33813.

324. Lee C-H , Rola H Ali RH, Rouzbahman M 2, Marino-Enriquez A, Isphording A, Zhu M, Guo X, BrunnerAL, Chiang S, Gilks CB, Nielsen TO, **Dal Cin P**, Robert B West RB,van de Rijn M, Oliva E, Fletcher JA, Nucci MR. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 2012, 36:1562-1570.

325. Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, **Dal Cin P**, Fernandes SM, Thompson C, MacConaill L, Wu1 CJ, Van de Peer Y, Correll M, Regev A, Neuberg D, Freedman AS. Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2012, 18:3791-3802.

326. Qian X, Hornick JL, Cibas ES, **Dal Cin P**, Domanski HA. Angiomatoid fibrous histiocytoma: A series of five cytologic cases with literature review and emphasis on diagnostic pitfalls. Diagn Cytopathol 2012; Aug;40 Suppl 2:E86-93.

327. Doyle LA, Wang WL, **Dal Cin P**, Lopez-Terrad D, Mertens F, Lazar A , Fletcher CDM, Hornick JL. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am J Surg Path 2012; 36:1444-51.

328. Sioletic S, **Dal Cin P**, Fletcher CDM, Hornick JL .Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: Analysis of 56 cases. Histopathology 2013; 62 :287-93.

329. Boni A, Lisovsky M, **Dal Cin P**, Rosenberg AE, Srivastava A. Atypical lipomatous tumor mimicking giant fibrovascular polyp of the esophagus: Report of a case and a critical review of literature. Hum Path 2013; 121:279-90.

330. Schwind S, Edwards CG, Nicolet D, Mrózek K, Maharry K,Wu Y-Z, Paschka P, Eisfeld A-K, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW,Kolitz JE, Blum W, Pettenati MJ, **Dal Cin P**, Carroll AJ, Caligiuri MA, Larson RA, Volinia S, Marcucci G, Bloomfield CD. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusion transcripts associates with distinct clinical and genetic features and lacks KIT mutations. Blood 2013; 121: 385-391.

331. Jo VJ, Antonescu CR, Zhang L, **Dal Cin P**, Hornick JL, Fletcher CDM. Cutaneous syncytial myoepithelioma: Clinicopathologic characterization in a series of 38 cases. Am J Surg Path 2013; 37:710-8.

332. Sadrzadeh H, Kerr DA , **Dal Cin P** , Lindeman NI , Hasserjian RP , Fathi AT. A unique PML-RARα rearrangement involving chromosomes 11, 15, and 17 in a patient with acute promyelocytic leukemia. Exp Hematol 2013; S0301-472X(13)00221-X.

333. La Starza R, Barba G, Valeria Nofrini V, Pierini T, Pierini V, Marcomigni L, Perruccio K, Matteucci C, Storlazzi CT, Daniele G, Crescenzi B, Giansanti M,Giovenali P, **Dal Cin P,** Mecucci C. Multiple EWSR1-WT1 and WT1-EWSR1 copies in 2 cases of desmoplastic round cell tumour. Cancer Genet 2013 206; 387-392.

334. Schoolmeester JK, Howitt BE, Hirsch MS, **Dal Cin P**, Bradley J. Quad BJ, Nucci MR. Perivascular Epithelioid Cell Neoplasm (PEComa) of the Gynecologic Tract: Clinicopathologic and Immunohistochemical Characterization of 16 Cases. Am J Surg Path 2014; 38:176-88.

335. Puliyel MM, Zhou S, Sapra A, **Dal Cin P**, French CA, Mascarenhas L, Venkatramani R. Nuclear protein in testis midline carcinoma misdiagnosed as adamantinoma. J Clin Onc 2014; 32:e57-60.

336. Mariño-Enríquez A, Hornick JL, **Dal Cin P**, Cibas ES, Qia X. Dedifferentiated liposarcoma and pleomorphic liposarcoma: A comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. Cancer Cytopath 2014; 122: 128-37.

337. Wu RI, Schorge JO, **Dal Cin P,** Young RH, Oliva E. Müllerian adenosarcoma of the uterus with low-grade sarcomatous overgrowth characterized by prominent hydropic change resulting in mimicry of a smooth muscle tumor. Int J Gynecol Path 2014; 33: 573-580.

338. Wojcik JB, Bellizzi AB, **Dal Cin P**, Bredella MA, Fletcher CDM, Hornicek F, Deshpande V, Hornick JL, Nielsen GP. Primary sclerosing epithelioid fibrosarcoma of bone: Analysis of a series. Am J Surg Pathol 2014; 38:1538-1544.

339. French CA, Rahman S, Walsh EM, Kuhnle S, Grayson A, Lemieux ME , Grunfeld N, Dr. Rubin BP, Antonescu CR, Zhang SZ, Venkatramani R , **Dal Cin P**, Howley PM. NSD3-NUT fusion oncoprotein

in NUT Midline Carcinoma: Implications for a novel oncogenic mechanism. Cancer Discov 2014; 4: 928-941.

340. Jacobsen ED; Pozdnyakova O, Redd R, Fisher DC; Noo P1, Dorfman D, **Dal Cin P**, Lacasce AS, Hochberg EP , Cote G, Shahsafaei G , Brown JR, Freedman AS. Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma 2014; 11:1-19.

341. Doyle LA, Wong KK, Bueno R, **Dal Cin P**, Fletcher JA, Sholl LM, Kuo F Ewing Sarcoma mimicking atypical carcinoid tumor: Detection of unexpected genomic alterations demonstrates the use of Next-Generation Sequencing as a diagnostic tool. Cancer Genetics 2014; 207:335-339.

342. Carey CD, Gusenleitner D, Chapuy B, Kovach AE, Kluk MJ,. Sun HH,. Crossland RE,Bacon C, Rand V, **Dal Cin P**, Le LP, Sohani AR, Shipp MA, Monti S, Rodig SJ. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. J Mol Diagn 2015; 17(1):19-30

343. Parra-Herran C, Quick CM, Yuan L, **Dal Cin P,** Bradley L. Quade BL, Nucci MR. Inflammatory myofibroblastic tumor of the uterus: Clinical and pathologic review of eight patients including a subset with aggressive clinical course. Am J Surg Path 2015; 39:157-68.

344. Howitt BE, Sholl LM, **Dal Cin P**, Jia Y, Yuan L, MacConaill L, Lindeman N, Kuo F, Garcia E, Nucci MR, Quade BJ. Targeted genomic analysis of Müllerian adenosarcoma. J Path 2015; 235:37-49

345. Movassaghian M, Sohani AR, McAfee SL, Perry AP, **Dal Cin P**, McLaughlin C, Fathi AT. Chromosome 17p deletion in a case of T-cell acute lymphoblastic lymphoma. Am J Hemat, 2015: 90: 264-8..

346. Cleven AHG, Nardi V, Ok CY, Goswami M, **Dal Cin P**, Zheng Z, Iafrate JA, Myrurgia A, Hamid MA, Wang SA, Hasserjian RP. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Modern Path, 2015, 28:552-63

347. Schoolmeester JK, Sciallis AP, Greipp PT, Hodge JC, **Dal Cin P**, Keeney GL, Nucci MR. Analysis of *MDM2* amplification in 43 endometrial stromal tumors: A potential diagnostic pitfall. Int J Gynecol Path 2015; 34(6):576-83.

348. Hornick JL, Sholl LM, **Dal Cin P**, Lovly CM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod Path 2015;. 28(5):732-9

349. Nardi V, Pulluqi O, Abramson JS, **Dal Cin P**, Hasserjian RP. Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. Am J Hemat 2015; 90(6):529-33.

350. Jalbut MM, Sohani AR, **Dal Cin P**, Hasserjian RP, Moran JA, Brunner AM, Fathi AT. Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. Leuk Res Rep. 201; 4(1):28-30.

351. Kluk MJ, Abo RP, BrownRD, Kuo FC, **Dal Cin P**, Pozdnyakova O, Morgan EA, Lindeman NI, DeAngelo DJ, AsterJC Myeloid Neoplasm Demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with ATRA-resistance identified by a custom next generation

sequencing assay. Cold Spring Harbor Molecular Case Studies, 2015; doi:10.1101/mcs.: a000307.

352. Davids MS, Vartanov A, Werner L, Neuberg D**, Dal Cin P**, Brown JR Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. Br J Haematol. 2015; 170:694-703.

353. Mirkovic J, Sholl LM, Garcia E , Lindeman N, MacConaill L, Hirsch M, **Dal Cin P**, Barletta JA, Nucci MR, McCluggage WG , Howitt BE. Targeted genomic profiling reveals recurrent KRAS mutations in mesonephric carcinomas of the female genital tract. Mod Path 2015; 28(11):1504-14.

354. Kluk MJ, Caleb H, Hongbo Y, Chen BJ, Neuberg DS, **Dal Cin P**, Woda BA, Pinkus GS, Rodig SJ. MYC immunohistochemistry to identify MYC-driven B-Cell lymphomas in clinical practice, Am J Clin Path, 2015, in press.

355. Mandelker D, **Dal Cin P**, Jacene H, Armand Ph, Richard Stone R; Lindeman N. Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol. 2015;4:30. doi: 10.1186/s40164-015-0026-x.

356. De Rienzo A, Archer MA, B Yeap BY, Dao N, Sciaranghella D, Sideris AC, Zheng Y, Holman AG, Wang YE, **Dal Cin P**, Fletcher JA, Rubio R, Croft L, Quackenbush J, Peter E, Sugarbaker PE, Munir KJ, Battilana JR, Gustafson CE, Chirieac LR, Ching SM, Wong J, Tay LC, Rudd S, Hercus R, Sugarbaker DJ, RichardsWG, Bueno R. Gender-specific molecular and clinical features underlie malignant pleural mesothelioma. Cancer Res 2016 ; 76(2):319-28.

357. Ordulu Z, Nucci MR , **Dal Cin P,** Hollowell M, Otis CN, Hornick JL, Park PJ, Kim TM, Quade BJ, Morton CC. Intravenous Leiomyomatosis: An unusual Intermediate between benign and malignant uterine smooth muscle tumors. Modern Path 2016; in press.

358. Van Dyke DL, Werner L, Rassenti LZ, Neuberg D, Ghia E, Heerema NA, **Dal Cin P**, Dell ' Aquilla M, Greaves A, Kipps T, Kay NE.. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukemia (CLL): The CLL research consortium experience. Br J Haematol 2016; in press

359. Parra-Herran C, Schoolmester JK, Yuan L, **Dal Cin P**, Quade BJ, Nucci MR. Myxoid leiomyosarcoma of the uterus: Clinico – pathologic features and differential diagnosis. Review of 30 cases. Am J Surg Path, 2016; 40: 285-301.

360. Howitt BE, **Dal Cin P**, Nucci MR, Quade BJ. Involvement of chromosome 8 in Müllerian Adenosarcoma. Int J Gynecol Path 2016; in press.

361. Attygalle AD, Vroobel K, Wren D, Barton DPJ, Hazell SJ, **Dal Cin P**, Koelble K , McCluggage G. An unusual case of YWHAE-NUTM2A/B endometrial stromal sarcoma with confinement to the endometrium and lack of high grade morphology. Int J Gynecol Path, in press 2016.

362. Wang SA, Tam W, Tsai, AG , Arber DA, Hasserjian RP, Geyer JT, George TI, Czuchlewski DR, Foucar K, Rogers HJ , Hs ED, Rea B, Bagg A, **Dal Cin P**, Zhao C, Kelley TW, Verstovsek S, Bueso-Ramos C, Orazi A. Targeted next generation sequencing identifies a subset of

idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified, Mod Path 2016; in press

Other peer-reviewed publications

1. **Dal Cin P**, Sandberg AA. Cytogenetic abnormalities and human cancer. ISI Atlas Science. Biochem 1988; 1: 273-278.

2. **Dal Cin P**, Sandberg AA. Chromosome changes in soft tissue tumors, benign and malignant. Cancer Invest 1989; 7: 63-76.

3. **Dal Cin P**, Sandberg AA. Chromosomal aspects of human oncogenesis. Crit Rev Oncogen 1989; 1: 113-126.

4. Van den Berghe H, **Dal Cin P**. Some aspects of chromosomes and oncogenes in hematologic malignancies. Biol Clin Hematológia 1989;11: 45-51

5. **Dal Cin P**, Trent JM. What should oncologists know about cytogenetics in solid tumors? Ann Oncol 1993; 4: 821-824.

6. **Dal Cin P**, Van den Berghe H. Cytogenetics of tumors of the female reproductive tract. Repro Med Rev 1994; 3: 1-10.

7. **Dal Cin P**, Van Den Berghe H. Ten Years of the cytogenetics of soft tissue tumors. Cancer Genet Cytogenet 1997; 95:59-66.

8. Dei Tos AP, **Dal Cin P**. The role of cytogenetics in the classification of soft tissue tumours. Virch Archiv 1997; 431:83-94.

9. Van Den Berghe H, **Dal Cin P**. Some genetic aspects of ovarian tumors. Eur J Obstet Gynecol 1998; 81:283-287.

10. **Dal Cin P**, Vanni R, Polito P, Van den Berghe H. Impatto diagnostico della citogenetica dei tumori solidi. Pathologica 1998; 90:337-342.

11. **Dal Cin P**, Polito P, Van den Berghe H. Genetica dei tumori renali. Pathologica 1998;90:101-107.

12. Losi L, **Dal Cin P**. Telomeres: Review of the literature. Pathologica 1999;91: 121-123.

13. **Dal Cin P**, Van Den Berghe H. Ligon A.H. Cytogenetics in the pathogenesis of uterine leiomyomas. Ref Gynecol Obstet 2000; 7:38-42.

14. Fletcher CDM, Fletcher JA, **Dal Cin P**, Ladanyi M, Woodruff JM. Diagnostic gold standard for

soft tissue tumours: morphology or molecular genetics? Histopathology 2001; 39:100-103.

15. Rubin BP, **Dal Cin P**. The genetics of lipomatous tumors. Semin Diagn Pathol 2001; 18:286-293.

16. Ladanyi M, Woodruff JM, Scheithauer BW, Bridge JA, Barr FG, Goldblum JR, Fisher C, Perez-Atayde A, **Dal Cin P**, Fletcher CD, Fletcher JA. Re: O'Sullivan MJ, Kyriakos M, Zhu X, Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD: Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod Pathol 2000; 13: 1336-46. Mod Pathol 2001; 14(7): 733-737.

17. Weinstein MH, **Dal Cin P**. Genetics of Epithelial Tumors of the Renal Parenchyma in Adults and Renal Cell Carcinoma in Children. Analyt Quant Cytol Histol 2001; 23:362-372.

18. **Dal Cin P**. Genetics in renal cell carcinoma. Current Opinion in Urology, 2003, 13:463-466.

19. **Dal Cin P,** Qian X, Cibas ES**.** The marriage of cytology and cytogenetics, Cancer Cytopathol, 2013, 121:279-290

20. Marino-Enriquez A, **Dal Cin P**. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genet, 2013, 206:357-373.

21. Antonescu CR, **Dal Cin P.** Promiscuous genes involved in recurrent chromosomal translocations in soft tissue tumours. Pathology 2014; 46:105-12.

Research publications without named authorship

1. Fourth MIC Cooperative Study Group. Meeting Report. Morphologic, Immunologic, and Cytogenetic Classification of the Chronic (mature) B and T Lymphoid Leukemias. Cancer Res 1990; 50: 2212.

2. Fourth MIC Cooperative Study Group. Meeting Report. A Conference on the Morphologic, Immunologic, and Cytogenetic Classification of the Chronic (mature) B and T Lymphoid Leukaemias. Cancer Genet Cytogenet 1990; 48:131-132.

3. Groupe Français de Cytogénétique Hématologique. Isochromosome 21q in hematologic malignancies. Cancer Genet Cytogenet 1991; 55: 101-105.

4. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD; Cancer and Leukemia Group B (CALGB). Blood. 2008; 111(11): 5371-5379.

5. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. *NOTCH1* mutations in CLL associated with trisomy 12. Blood. 2012; 119:329-331.

6. Balatti V, Lerner S, Rizzotto L, Rassenti LZ, Bottoni A, Palamarchuk A, Cascione L, Alder H, Keating MJ, Kipps TJ, Pekarsky Y, Croce CM. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia. 2013;27(3):740-3.

7. Walker A, Mrózek K, Kohlschmidt J, Rao KW, Pettenati MJ, Sterling LJ, Marcucci G, Carroll AJ, Bloomfield CD. New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and Leukemia Group B 8461.Genes Chromosomes Cancer. 2013;52(4):385-401.

Non-peer reviewed scientific or medical publications/materials in print or other media

Proceedings of meetings or other non-peer reviewed research publications

1. **Dal Cin P**, Van den Berghe H. i(12p) in germ cell tumors. Proceedings of the Satellite Meeting on Human Germ Cell Neoplasia, Groningen, The Netherlands, 1989 August. Recent Results in Cancer Research, vol. 123. Oosterhuis et al., eds Pathobiology of Human Germ Cell Neoplasia1991; 107-111.

2. **Dal Cin P**. Cytogenetics of soft tissue tumours. Proceedings of the German Society of Pathology. Guntel Kloppel eds. Gustav Fischer. Jena, Germany; 82 Tagun 1998; 82:47-58.

Reviews, chapters, monographs and editorials

1. **Dal Cin P**, Sandberg AA. Karyotypic analysis of solid tumors. In: Current Topics in Pathology: Pathology of the Nucleus. J.C.E. Underwood, Ed Berlin: Springer-Verlag; 1990.

2. **Dal Cin P**, Van den Berghe H. Chromosome abnormalities in benign prostatic hyperplasia. In: Innovations in the Management of Benign Prostatic Hyperplasia. Heidelberg: Petrovich Z, Baert L, eds Springer Verlag; 1994; 49-56.

3. Vanni R, **Dal Cin P**. Involvement of chromosome 12 in uterine leiomyoma. In: Chromosome 12 Aberrations in Human Solid Tumors. Cytogenetics and Molecular Genetics. Bullerdick J and Bartnitzke S eds; Berlin, Heidelberg, New York: Springer Verlag; 1994; 16-26.

4. Schoenmakers EFPM, Kazmierczak B, Kools PFJ, Mols R, **Dal Cin P**, Bullerdiek J, Van den Berghe H, Van de Ven WJM. Development and characterization of cell lines from a myxoid liposarcoma with t(12;16)(q13;p11.2) and trisomy 8. In: Chromosome 12 Aberrations in Human Solid Tumors. Cytogenetics and Molecular Genetics. Bullerdick J and Bartnitzke S eds; Berlin, Heidelberg, New York: Springer Verlag; 1994; 138-151.

5. Herrmann ME, Belge G, Stern C, **Dal Cin P**, Bullerdiek J, Bartnitzke S. Breakpoints and recipient chromosomes in pleomorphic adenomas, lipomas, and uterine leiomyomas - what do they tell us? In: Chromosome 12 Aberrations in Human Solid Tumors. Cytogenetics and Molecular Genetics. Bullerdick J and Bartnitzke S eds; Berlin, Heidelberg, New York: Springer Verlag; 1994; 46-52.

6. Kazmierczak B, Bartnitzke S, **Dal Cin P**, Vanni R, Bullerdiek J. Cell lines from tumours showing 12q13-15 aberrations. In: Chromosome 12 Aberrations in Human Solid Tumors. Cytogenetics and Molecular Genetics. Bullerdick J and Bartnitzke S eds; Berlin, Heidelberg, New York: Springer Verlag; 1994; 89-102.

7. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Bosly A, Doyen C, Carli G, Piva N, Castoldi G, Stul M, **Dal Cin P**, Cassiman JJ, Van den Berghe H. Clinical review on features and cytogenetic patterns in adult acute myeloid leukemia with lymphoid markers. In: Leukemia & Lymphoma Review Series. Polliack A, eds; Harwood Academic Publishers; 1995; 13-19.

8. Van den Berghe H, **Dal Cin P**. Chromosomes and Cancer .In: Oxford Textbook of Oncology. Peckham M, Pinedo B, Veronesi U, eds; Oxford University Press; 1995; 32-45.

9. **Dal Cin P**, Van den Berghe H. Chromosome abnormalities in adenocarcinoma of the prostate. In: Carcinoma of the Prostate. Innovations in Management. Petrovich Z, Baert L. and Brady LW, eds; Berlin, Heidelberg: Springer Verlag ;1996; 51-54.

10. **Dal Cin P**, Van den Berghe H. Chromosomal abnormalities in adipose tissue tumors. In: Lipomatous Tumors: Diagnosis and Primary Treatment. De Wever I, Stas M, eds; Surgical Oncology Series vol. 4. Leuven: Leuven University Press; 1997; 31-41.

11. **Dal Cin P**, Van den Berghe H. Cytogenetics of mesenchymal tumors of the uterus. In: Pathogenesis and Medical Management of Uterine Fibroids. Brosens I, Lunenfeld B and Donnez J eds. Parthenon Publishing 1999; 55-59.

12. Brosens I, **Dal Cin P**, Deprest J, Van den Berghe H. Clinico-pathological features of uterine leiomyomas. In: Pathogenesis and Medical Management of Uterine Fibroids. Brosens I, Lunenfeld B and Donnez J eds. Parthenon Publishing 1999; 99-110.

13. **Dal Cin P**, Van den Berghe H. Genetics of renal cell carcinoma. In: Carcinoma of the kidney, testis and uncommon tumors of the genitourinary tract. Petrovich Z, Baert L and Brady LW, eds. Innovations in management. Springer-Verlag Berlin, Heidelberg; 1999; 25-31.

14. Aubain Somerhausen N, **Dal Cin P**. Giant cell tumour of tendon sheath. In: World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F, eds; Lyon: IARC Press, 2002; 110-111.

15. Aubain Somerhausen N, **Dal Cin P**. Diffuse-type giant tumour. In: World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F, eds; Lyon: IARC Press, 2002; 112-114.

16. Nascimento AG, **Dal Cin P**. Plexiform fibrohistiocytic tumour. In: World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F, eds; Lyon: IARC Press, 2002; 116-117.

17. **Dal Cin P**. Metaphase harvest and cytogenetic analysis of malignant hematological specimen. In: Current Protocols in Human Genetics, Drapoli NC, Haines JL, Korf BR, Morton CC, Seidman CE, Seidman JG, Smith DR, eds. Wiley and Sons Inc. Rockville, MD 2002; 10.2.1-10.2.12.

18. **Dal Cin P**, Morton CC. Cytogenetics for the hematologist. In: Blood: Principles and Practice of Hematology. Handin RI, Lux SE, Stossel TP, eds; Philadelphia: JB Lippincott; 2003; 96-122.

19. Polito P, **Dal Cin P**, Debiec-Rychter M, Hagemeijer A. Human Solid Tumors: Cytogenetics techniques. In: Methods in Molecular Biology. Cytogenetics: Methods and Protocols. G.J. Swansbury ed. Humana Press, Totowa, NJ. 2003; 220:135-150.

20. Ligon AH, Morton CC, Bieber FR, Fletcher JA, Giersch AB, Lee C, Sandstrom M, Weremowicz S, Xiao S, **Dal Cin P**. Reporting of diagnostic cytogenetic results. In: Current Protocols in Human Genetics. Dracopoli NC, Haines JL, Korf BR, Morton CC, Seidman CE, Seidman JG, Smith DR, eds. Wiley & Sons, Rockville, MD; 2004; Supplement 43, p.A.1D.1 - A1D.27.

21. **Dal Cin P**, Morton CC. Cytogenetic and other genetic insights into the pathogenesis of uterine leiomyomata. In: Uterine Leiomyomata: Pathogenesis and Management. Brosens I ed. Taylor and Francis, London, England. 2006; 11-23.

22. Ladanyi M, Antonescu C, **Dal Cin P**. Molecular genetics and cytogenetics analysis of soft tissue tumors. In: Enzinger &Weiss Soft Tissue Tumors, 5th Ed. Weiss SW, Goldblum JR eds. Mosby Inc.2007; 73-102.

23. Lindeman N, **Dal Cin P**. Molecular testing for solid tumors. In: Essential of Molecular Genetic Pathology. Cheng L, Zhang D. eds. Human Press Inc.Totowa, NJ. 2007; 467-495.

24. **Dal Cin P**, Ligon A. Tumors of the urinary tract. In: Cancer Cytogenetics, 3rd Edition. Heim S, Mitelman F eds. John Wiley & Sons, Inc. NJ, 2009; 465-493.

25. Palacios Calvo J, **Dal Cin P**. Molecular pathology and cytogenetics and endometrial carcinoma, carcinosarcoma, and uterine sarcomas. Uterine Cancer: Screening, Diagnosis, and Treatment. In: Current Clinical Oncology. Muggia F, Olivia E eds. The Human Press Inc. 2009; 87-104.

26. **Dal Cin P**. Cytogenetics of mesenchymal tumors of the female genital tract. In: Current concepts in gynecologic pathology: Mesenchymal tumors of the female genital tract. Olivia E eds. Surgical Pathology Clinics. 2009; 813-821.

27. **Dal Cin P**, Aster JC, DeAngelo DJ. When to go FISHing. Am J Surg Path, 2010; 133: 351-353.

28. Ligon AH, Morton CC, Bieber FR, Fletcher JA, Giersch AB, Kantarci S, Leach N, Lee C, Sandstrom M, Weremowicz S, Xiao S, **Dal Cin P**. Reporting of diagnostic cytogenetic results. In: Current Protocols in Human Genetics. Dracopoli NC, Haines JL, Korf BR, Morton CC, Seidman

CE, Seidman JG, Smith DR, eds. Wiley & Sons, Rockville, MD; 2010; Supplement 43, p. A.1D.1 – A.1D.27.

29. Hasserjian RP, **Dal Cin P**. Deletion of chromosome 20q: Friend or foe? Leuk Res 2011; 35: 844-845.

30. Ligon AH, Morton CC, Bieber FR, Fletcher JA, Giersch AB, Kantarci S, Leach N, Lee C, Sandstrom M, Weremowicz S, Xiao S, **Dal Cin P**. Reporting of diagnostic cytogenetic results. In: Current Protocols in Human Genetics. Dracopoli NC, Haines JL, Korf BR, Morton CC, Seidman CE, Seidman JG, Smith DR, eds. Wiley & Sons, Rockville, MD; 2011; p.A.1 D.1

31. **Dal Cin P**, McLaughlin C. Metaphase Harvest and Cytogenetic Analysis of Malignant Hematological Specimens. In: Current Protocols in Human Genetics. Wiley & Sons, Inc. 2012; 73:10.2.1-10.2.15.

32. Lindeman NI, **Dal Cin P**. Molecular Pathology of Soft Tissues and Bones tumors. In: Molecular Genetic Pathology 2nd ed. Springer, New York, NY; 2013; 325-356.

33. Sciot R, **Dal Cin P**. Fibroma of tendon sheath. In: World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Bridge JA, Hoogendoorn PCW, Mertens F, eds; Lyon: IARC Press, 20113; 59-60.

34. Oda Y, **Dal Cin P**, Laskin WB. Epitheliod sarcoma. In: World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Bridge JA, Hoogendoorn PCW, Mertens F, eds; Lyon: IARC Press, 2013; 216-218.

35. Siegal GP, Bianco P, **Dal Cin P**. Fibrous dysplasia. In: World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Bridge JA, Hoogendoorn PCW, Mertens F, eds; Lyon: IARC Press, 2013; 352-353.

36. Ladanyi M, Fletcher JA, **Dal Cin P**. Molecular genetics and cytogenetics analysis of soft tissue tumors. In: Enzinger &Weiss Soft Tissue Tumors, 6th Ed. Weiss SW, Goldblum JR eds. Mosby Inc. 2014, 76-109.

37. **Dal Cin P**. Tumors of the urinary tract. In: Cancer Cytogenetics, 4rd Edition. Heim S, Mitelman F eds. John Wiley & Sons, Inc. NJ, 2015, 401-425.

38. Hirsch MS, Signoretti S, **Dal Cin P**. Adult renal cell carinomas: A review of established entities from morphology to molecular genetics. Genitourinary Pathology. In: Surg Pathol Clin. Hirsch MS, Goldblum JR eds, 2015; 8(4):587-621

39. Palacios J, **Dal Cin P**. Molecular pathology and cytogenetics of endometrial carcinoma, carcinosarcoma, and uterine sarcomas. Uterine Cancer: Screening, Diagnosis, and Treatment. In: Current Clinical Oncology. Muggia F, Olivia E eds. The Human Press Inc. 2015, in press.

Professional Educational Materials or Reports, in print or other media

2001 **Dal Cin P**. Fibrous dysplasia of the bone. Atlas Genet Cytogenet Oncol Haematol.
http://www.infobiogen.fr/services/chromcancer/Tumors/FibDysplasiaBoneID5093.html
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists

2001 **Dal Cin P.** Chromophobe renal cell carcinoma. Atlas Genet Cytogenet Oncol Haematol.
http://www.infobiogen.fr/services/chromcancer/Tumors/CromophobeRenalID5124.html
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists

2002 **Dal Cin P.** Bone: Aneurysmal bone cysts. Atlas Genet Cytogenet Oncol Haematol.
http://www.infobiogen.fr/services/chromcancer/Tumors/AneurBoneCystID5133.html
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists

2003 **Dal Cin P.** Soft Tissue Tumors. Atlas Genet Cytogenet Oncol Haematol.
http://www.infobiogen.fr/services/chromcancer/Tumors/softissuTumID5042.html
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists

2003 **Dal Cin P.** Intravenous leiomyomatosis. Atlas Genet Cytogenet Oncol Haematol.
http://www.infobiogen.fr/services/chromcancer/Tumors/IntravLeiomyomID5158.html
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists

2005- Manual of Surgical Pathology
http://labmed.bwh.harvard.edu/pathology/Manual/Manual_Index.htm
Intended audience: All staff members of BWH pathology.
Also distributed to Faulkner Hospital and Children's Hospital.

2007 **Dal Cin P.** Yee AJ, Dey B. A *de novo* AML with a t(1;21)(p36;q22) in an elderly patient. Atlas Genet Cytogenet Oncol Haematol.
http://atlasgeneticsoncology.org/Reports/0121DalCinID100021.html
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists

2007 **Dal Cin P**, Ouahchi K. t(16;21)(q24;q22) in therapy-related acute myelogenous leukemia arising from myelodysplastic syndrome. Atlas Genet Cytogenet Oncol Haematol.
http://atlasgeneticsoncology.org/Reports/1621DalCinID100022.html
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists

2007 **Dal Cin P**, DeAngelo DJ, Stone RM. A t(4;12)(q11;p13) in a patient with coincident CLL at the same time of AML diagnosis. Atlas Genet Cytogenet Oncol Haematol.
http://AtlasGeneticsOncology.org/Reports/0412DalCinID100023.html
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists.

2012 Lee RE, **Dal Cin P** . +13 or trisomy 13. Atlas Genet Cytogenet Oncol Haematol..
URL : http://AtlasGeneticsOncology.org/Anomalies/Tri13ID1033.html
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists.

2013 **Dal Cin P.** Soft Tissue Tumors. Atlas Genet Cytogenet Oncol Haematol.
http://www.infobiogen.fr/services/chromcancer/Tumors/softissuTumID5042.html

Intended audience: International cytogeneticists, hematologists, oncologists, pathologists

2013 Simmons D, **Dal Cin P**, Kuo FC. Diagnosis: Acute Myeloid Leukemia, NOS and MYC amplification & promyelocytic differentiation. Case of the quarter, August 2013. http://www.sh-eahp.org/images/SH_kuo/COQ_Simmons_etal.pdf
Intended audience: International cytogeneticists, hematologists, oncologists, pathologists.

2014 Morgan EA, **Dal Cin P.** t(5;9)(q14.1;p24) SSBP2/JAK2. Atlas Genet Cytogenet Oncol Haematol. http://atlasgeneticsoncology.org/Anomalies/t0509q14p24ID1680.html

Theses

1. **Dal Cin P.** Sister chromatid exchanges induced by BrDU in human lymphocytes cultures [M.Sc dissertation]. Padova (Italy): University of Padua, 1977.

2. **Dal Cin P.** Cytogenetics studies in soft tissue tumors. [Ph.D.dissertation]. Pavia (Italy): Unversity of Pavia, 1986.

Narrative Report

I am a clinical cytogeneticist with a major interest and expertise in cancer genetics and cytogenetics. My primary responsibility (~85%) is diagnostic molecular and conventional cytogenetics of neoplasms in the Partners Clinical Cytogenetics Laboratory. This Laboratory is located in the Center for Advanced Molecular Diagnosis in the Department of Pathology at the Brigham and Women's Hospital. The remainder of my professional time involves translational research collaborations and teaching.

My clinical and research work have focused on the primary discovery of many of the characteristic chromosome aberrations in hematological and solid tumor malignancies, particularly soft tissue tumors. Identification of these genetic changes is critical in the differential diagnosis and clinical care of patients with such tumors. I developed and pioneered the method of collagenase treatment for tumor disaggregation (REF 2), which was adopted by the field as the standard technique for assesing chromosome abnormalities in solid tumors. These methods allowed me to provide many of first description of specific translocations in benign and malignant soft tissue tumors and, more importantly, to identify karyotypic features that permit discrimination of benign from malignant proliferations. I was also the first to describe many of the specific karyotypic changes in mesenchymal/bone tumors that lead to discovery of the fusion genes in benign and abnormal cellular proliferations e.g. the 12q14.3 in many benign lesions, t(X;18) in synovial sarcoma, t(12;16) in myxoid liposarcoma, the t(1;2) in pigmented nodular tenosinovitiis, in the 8q12 in lipoblastoma, t(7;17) and t(10;17) in endometrial stromal sarcoma, t(15;19) in midline carcinoma, t(16;17) in aneurysmal bone cysts, t(2;22) in clear cell sarcoma and in angiomatoid fibrous histiocytoma, t(11;16) in chondroid lipoma, the 2q35 translocation variants alveolar rhabdomyosarcoma, t(6;22) in soft tissue myoepitheliomas and 8q13 reqrrangement in mesenchymal chondrosarcoma . In addition, my work has contributed to improved physiopathologic insights and clinically useful delineation of tumor entities, as well as identification of prognostic parameters. I have developed highly productive working relationships with faculty, residents, and researchers from many institutions both in the Longwood Medical Area and internationally. This body of work is described in my peer-reviewed publications (331) in the last 20 years.

During the decade beginning in 1988, I worked as a Senior Scientist at the Centre for Human Genetics of the University of Leuven, a large integrated centre with over 200 employees attracting many European, Asian, and

U.S. post-graduate fellows in the various medical disciplines. My responsibilities included formal and practical teaching of clinical and molecular genetics of solid tumors. In 1999, I joined the Faculty of Medicine at Harvard as Associate Professor and I participate actively in teaching of students and post-graduate fellows. This includes lecturing in the HMS post-graduate courses, "Advances in Cytology" and "Bone and Soft Tissue Pathology for Surgical Pathologists". I have delivered numerous invited lectures nationally and internationally. Locally, in the Longwood Medical Area, I have been active in the laboratory education of post-doctoral fellows enrolled in our American Board of Medical Genetics training program. I also teach pathology residents and molecular genetic pathology fellows from both BWH and MGH. I am the designated cytogeneticist responsible for coordinating a monthly Hematopathology-Cytogenetics conference at MGH. In a similar capacity, I review all of the cytogenetic findings for cases presented at the weekly BWH Sarcoma Clinic Working Conference and the DFCI Oncology Pathology Conference. At the national level, I am responsible for reporting cytogenetic findings for patients enrolled in national clinical trials, such as the Cancer and Leukemia Group B (CALGB), Children's Oncology Group (COG) and Chronic Lymphocytic Leukemia Research Consortium (CLLRC). I recently became a permanent member of the CALGB karyotype review committee. I am also involved in the introduction of new cytogenetic protocols into laboratory practice.

My professional efforts have fully integrated the tripartite mission of academic medical centers including laboratory diagnostic service, research collaborations, and the education of the next generation of medical scientists and clinicians. My discoveries of characteristic chromosomal rearrangements in solid tumors has had a large impact by allowing improved correlation with parameters such as tumor biology, tumor morphology and immunophenotype, and identification of appropriate targeted therapies. Further refinement of these chromosomal breakpoints using molecular techniques has led to development of contemporary diagnostic assays, principally FISH and RT-PCR now widely implemented in clinical laboratory diagnostic practice.